{  "http://dbpedia.org/resource/Ministry_of_Health_(Bahrain)" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Morocco" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Ramon_Tulfo" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://en.wikipedia.org/wiki/Sinopharm_BIBP_COVID-19_vaccine" : { "http://xmlns.com/foaf/0.1/primaryTopic" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Inactivated_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Timeline_of_the_COVID-19_pandemic_in_Indonesia_(2021)" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Iran" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" : { "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ { "type" : "uri", "value" : "http://dbpedia.org/ontology/Drug" } ,      { "type" : "uri", "value" : "http://www.w3.org/2002/07/owl#Thing" } ,      { "type" : "uri", "value" : "http://dbpedia.org/ontology/ChemicalSubstance" } ,      { "type" : "uri", "value" : "http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject" } ,      { "type" : "uri", "value" : "http://dbpedia.org/ontology/Vaccine" } ,      { "type" : "uri", "value" : "http://www.wikidata.org/entity/Q8386" } ] ,    "http://www.w3.org/2000/01/rdf-schema#label" : [ { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "it" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "fr" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "de" } ,      { "type" : "literal", "value" : "Vacuna de Sinopharm contra la COVID-19" , "lang" : "es" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "ca" } ,      { "type" : "literal", "value" : "\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0COVID-19\u30EF\u30AF\u30C1\u30F3" , "lang" : "ja" } ,      { "type" : "literal", "value" : "Vakcino de la kronvirusa malsano de 2019 de Sinopharm BIBP" , "lang" : "eo" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "ar" } ,      { "type" : "literal", "value" : "\u773E\u611B\u53EF\u7DAD2019\u51A0\u72C0\u75C5\u6BD2\u75C5\u75AB\u82D7" , "lang" : "zh" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "sv" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "pt" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "uk" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "nl" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "in" } ,      { "type" : "literal", "value" : "Vakc\u00EDna Sinopharm BIBP proti covidu-19" , "lang" : "cs" } ,      { "type" : "literal", "value" : "Sinopharm BIBP COVID-19 vaccine" , "lang" : "en" } ,      { "type" : "literal", "value" : "\uC2DC\uB178\uD31C BBIBP-CorV \uCF54\uB85C\uB09819 \uBC31\uC2E0" , "lang" : "ko" } ,      { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "ru" } ] ,    "http://www.w3.org/2000/01/rdf-schema#comment" : [ { "type" : "literal", "value" : "BBIBP-CorV, ook bekend als het Sinopharm-COVID-19-vaccin is een van de twee ge\u00EFnactiveerde COVID-19-vaccins die door zijn ontwikkeld. Eind december 2020 was het in fase III-onderzoek in Argentini\u00EB, Bahrein, Egypte, Marokko, Pakistan, Peru en de Verenigde Arabische Emiraten (VAE) met meer dan 60.000 deelnemers. BBIBP-CorV gebruikt een gelijkaardige technologie als CoronaVac en BBV152, andere ge\u00EFnactiveerde virusvaccins voor COVID-19." , "lang" : "nl" } ,      { "type" : "literal", "value" : "La BBIBP-CorV \u00E9s una de les dues vacunes contra la COVID-19 de virus inactivats que desenvolupa Sinopharm. A desembre de 2020, es troba en proves de fase III a Argentina, Bahrain, Egipte, Marroc, Pakistan, Per\u00FA i els Emirats \u00C0rabs Units (EAU) amb m\u00E9s de 60.000 participants. Al novembre, a gaireb\u00E9 un mili\u00F3 de persones se'ls havia administrat la vacuna mitjan\u00E7ant el programa d'\u00FAs d'emerg\u00E8ncia de la Xina. Al desembre, gaireb\u00E9 100.000 persones als Emirats \u00C0rabs Units tamb\u00E9 havien rebut la vacuna." , "lang" : "ca" } ,      { "type" : "literal", "value" : "La vakcino kontra\u016D la kronvirusa malsano de 2019 de Sinopharm BIBP, anka\u016D nomita BBIBP-CorV, la vakcino kontra\u016D la kronvirusa malsano de 2019 de Sinopharm, a\u016D vakcino BIBP, estas unu el du vakcinoj kontra\u016D la kronvirusa malsano de 2019 de malaktivigitaj virusoj, kiujn kreis la Instituto de Biologiaj Produktoj de Pekino de Sinopharm (BIBP a\u016D BBIBP). \u011Ci finis triafazajn provojn en Argentino, Barejno, Egiptio, Maroko, Pakistano, Peruo, kaj la Unui\u011Dintaj Arabaj Emirlandoj (UAE) kun pli ol 60 000 partoprenantoj. BBIBP-CorV uzas similan teknologion kiel CoronaVac kaj Covaxin, aliaj vakcinoj de malaktivigitaj virusoj kontra\u016D la kronvirusa malsano de 2019. \u011Cia produkta nomo estas Vakcino SARS-CoV-2 (Vero Cell), kvankam CoronaVac havas vakcinon kun simila nomo." , "lang" : "eo" } ,      { "type" : "literal", "value" : "BBIBP-CorV est l'un des deux vaccins \u00E0 virus inactiv\u00E9 contre la COVID-19 con\u00E7u par la soci\u00E9t\u00E9 chinoise Sinopharm. Il est approuv\u00E9 par l'OMS depuis le 10 mai 2021 (autorisation d'utilisation d'urgence) et est utilis\u00E9 dans 60 pays dont la Chine, les \u00C9mirats arabes unis, le Maroc, l'Alg\u00E9rie, l'Argentine, le Bahrein, le P\u00E9rou, l'\u00C9gypte, le Kazakhstan, le S\u00E9n\u00E9gal et le Nigeria." , "lang" : "fr" } ,      { "type" : "literal", "value" : "\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0COVID-19\u30EF\u30AF\u30C1\u30F3\uFF08\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u30B3\u30D3\u30C3\u30C919\u30EF\u30AF\u30C1\u30F3\uFF09\u306F\u3001BBIBP-CorV\u3068\u3082\u547C\u3070\u308C\u3001\u4E2D\u56FD\u306E\u56FD\u55B6\u4F01\u696D\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u793E\u304C\u958B\u767A\u3057\u305F2\u7A2E\u985E\u306E\u4E0D\u6D3B\u5316\u30A6\u30A4\u30EB\u30B9COVID-19\u30EF\u30AF\u30C1\u30F3\u306E\u3046\u3061\u306E1\u3064\u3067\u3042\u308B\u30022020\u5E7412\u6708\u4E0B\u65EC\u3001\u30A2\u30EB\u30BC\u30F3\u30C1\u30F3\u3001\u30D0\u30FC\u30EC\u30FC\u30F3\u3001\u30A8\u30B8\u30D7\u30C8\u3001\u30E2\u30ED\u30C3\u30B3\u3001\u30D1\u30AD\u30B9\u30BF\u30F3\u3001\u30DA\u30EB\u30FC\u3001\u30A2\u30E9\u30D6\u9996\u9577\u56FD\u9023\u90A6\uFF08UAE\uFF09\u3067\u7B2CIII\u76F8\u81E8\u5E8A\u8A66\u9A13\u304C\u884C\u308F\u308C\u300160,000\u4EBA\u4EE5\u4E0A\u304C\u53C2\u52A0\u3057\u305F\u3002 12\u67089\u65E5\u3001UAE\u306F\u3001BBIBP-CorV\u304CCOVID-19\u611F\u67D3\u75C7\u306B\u5BFE\u3057\u306686\uFF05\u306E\u6709\u52B9\u6027\u3092\u793A\u3057\u305F\u7B2CIII\u76F8\u8A66\u9A13\u306E\u4E2D\u9593\u7D50\u679C\u3092\u767A\u8868\u3057\u300112\u6708\u4E0B\u65EC\u306B\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u306F\u3001\u5185\u90E8\u5206\u6790\u306779\uFF05\u306E\u6709\u52B9\u6027\u304C\u793A\u3055\u308C\u305F\u3068\u767A\u8868\u3057\u305F\u30022021\u5E745\u6708\u306B\u306F\u30EF\u30AF\u30C1\u30F3\u3092\u627F\u8A8D\u3057\u305F\u4E16\u754C\u4FDD\u5065\u6A5F\u95A2\uFF08WHO\uFF09\u304C\u6709\u52B9\u6027\u309279\uFF05\u3068\u63A8\u5B9A\u3057\u305F\u3002\u30D5\u30A1\u30A4\u30B6\u30FC-\u30D0\u30A4\u30AA\u30F3\u30C6\u30C3\u30AFCOVID-19\u30EF\u30AF\u30C1\u30F3\u3084\u30E2\u30C7\u30EB\u30CAmRNA-1273\u306E\u3088\u3046\u306AmRNA\u30EF\u30AF\u30C1\u30F3\u306F90%\u4EE5\u4E0A\u306E\u9AD8\u3044\u6709\u52B9\u6027\u3092\u793A\u3057\u3066\u3044\u308B\u304C\u3001\u3053\u308C\u3089\u306E\u30EF\u30AF\u30C1\u30F3\u306F\u8D85\u4F4E\u6E29\u51B7\u51CD\u5EAB\u3068\u8F38\u9001\u8ECA\u3092\u5FC5\u8981\u3068\u3059\u308B\u305F\u3081\u3001\u4E00\u90E8\u306E\u56FD\u3067\u306F\u6D41\u901A\u4E0A\u306E\u8AB2\u984C\u3068\u306A\u3063\u3066\u3044\u308B\u3002BIBP-CorV\u306F\u3001\u901A\u5E38\u306E\u51B7\u8535\u6E29\u5EA6\u3067\u8F38\u9001\u30FB\u4FDD\u5B58\u304C\u53EF\u80FD\u3067\u3042\u308B\u3002 BBIBP-CorV\u306F\u3001\u7B2CIII\u76F8\u8A66\u9A13\u3067\u958B\u767A\u304C\u9032\u3081\u3089\u308C\u3066\u3044\u308BCOVID-19\u7528\u4E0D\u6D3B\u5316\u30A6\u30A4\u30EB\u30B9\u30EF\u30AF\u30C1\u30F3\u3067\u3042\u308BCoronaVac\u3084BBV152\u3068\u540C\u69D8\u306E\u3001\u3088\u308A\u4F1D\u7D71\u7684\u306A\u6280\u8853\u3092\u5171\u6709\u3057\u3066\u3044\u308B\u3002" , "lang" : "ja" } ,      { "type" : "literal", "value" : "La vacuna de Sinopharm contra la COVID-19 (de nombre en clave BBIBP-CorV) conocida a veces como Vero Cell o Sinopharm, es una vacuna contra la COVID-19 de virus inactivado, desarrollada por Sinopharm (China).\u200B La vacuna complet\u00F3 los ensayos cl\u00EDnicos de fase III en los Emiratos \u00C1rabes Unidos, Argentina, Bar\u00E9in, Egipto, Marruecos, Pakist\u00E1n y Per\u00FA, con m\u00E1s de 60 000 personas.\u200B\u200B BBIBP-CorV se est\u00E1 utilizando en campa\u00F1as de vacunaci\u00F3n en ciertos pa\u00EDses de Asia,\u200B\u200B\u200B \u00C1frica,\u200B\u200B\u200B Am\u00E9rica del Sur,\u200B\u200B\u200B y Europa.\u200B\u200B\u200B Sinopharm espera producir mil millones de dosis de BBIBP-CorV en 2021.\u200B" , "lang" : "es" } ,      { "type" : "literal", "value" : "Vakc\u00EDna Sinopharm BIBP proti covidu-19, tak\u00E9 zn\u00E1m\u00E1 jako BBIBP-CorV, vakc\u00EDna Sinopharm COVID-19, nebo BIBP vakc\u00EDna, je jedn\u00EDm ze dvou inaktivovan\u00FDch vakc\u00EDn proti nemoci COVID-19 vyvinut\u00E9 Pekingsk\u00FDm institutem biologick\u00FDch produkt\u016F Sinopharm (n\u011Bkdy ozna\u010Dovan\u00FD jako Pekingsk\u00FD bio-Institut biologick\u00FDch produkt\u016F, co\u017E vede ke dv\u011Bma r\u016Fzn\u00FDm zkratk\u00E1m BBIBP a BIBP pro stejnou vakc\u00EDnu). Pro vakc\u00EDnu byla dokon\u010Dena f\u00E1ze III zkou\u0161ek v Argentin\u011B, Bahrajnu, Egypt\u011B, Maroku, P\u00E1kist\u00E1nu, Peru a Spojen\u00FDch arabsk\u00FDch emir\u00E1tech (SAE) s v\u00EDce ne\u017E 60 000 \u00FA\u010Dastn\u00EDky. BBIBP-CorV sd\u00EDl\u00ED podobnou technologii s CoronaVac a , dal\u0161\u00EDmi inaktivovan\u00FDmi virov\u00FDmi vakc\u00EDnami proti covidu-19. N\u00E1zev jeho produktu je SARS-CoV-2 Vakc\u00EDna (Vero Cell), nezam\u011B\u0148ujte s podobn\u00FDm n\u00E1zvem - CoronaVac." , "lang" : "cs" } ,      { "type" : "literal", "value" : "The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine (Vero Cell), not to be confused with the similar product name of CoronaVac." , "lang" : "en" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u2014 \u043E\u0434\u043D\u0430 \u0438\u0437 \u0434\u0432\u0443\u0445 \u0446\u0435\u043B\u044C\u043D\u043E\u0432\u0438\u0440\u0438\u043E\u043D\u043D\u044B\u0445 \u0438\u043D\u0430\u043A\u0442\u0438\u0432\u0438\u0440\u043E\u0432\u0430\u043D\u043D\u044B\u0445 \u0432\u0430\u043A\u0446\u0438\u043D \u043F\u0440\u043E\u0442\u0438\u0432 COVID-19, \u0440\u0430\u0437\u0440\u0430\u0431\u0430\u0442\u044B\u0432\u0430\u0435\u043C\u044B\u0445 Sinopharm. \u0412\u0430\u043A\u0446\u0438\u043D\u0430 \u0434\u0432\u0443\u0445\u0434\u043E\u0437\u043E\u0432\u0430\u044F, \u0434\u043B\u044F \u0432\u043D\u0443\u0442\u0440\u0438\u043C\u044B\u0448\u0435\u0447\u043D\u044B\u0445 \u0438\u043D\u044A\u0435\u043A\u0446\u0438\u0439 \u0441 \u0438\u043D\u0442\u0435\u0440\u0432\u0430\u043B\u043E\u043C \u043C\u0435\u0436\u0434\u0443 \u0438\u043D\u044A\u0435\u043A\u0446\u0438\u044F\u043C\u0438 3\u20144 \u043D\u0435\u0434\u0435\u043B\u0438. \u0425\u0440\u0430\u043D\u0438\u0442\u0441\u044F \u043F\u0440\u0438 \u0442\u0435\u043C\u043F\u0435\u0440\u0430\u0442\u0443\u0440\u0435 2\u20138 \u00B0C. 9 \u0434\u0435\u043A\u0430\u0431\u0440\u044F 2020 \u0433\u043E\u0434\u0430 \u041E\u0410\u042D \u043E\u0431\u044A\u044F\u0432\u0438\u043B\u0438 \u043E\u0431 \u043E\u0444\u0438\u0446\u0438\u0430\u043B\u044C\u043D\u043E\u0439 \u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0430\u0446\u0438\u0438 BBICP-CorV \u043F\u043E\u0441\u043B\u0435 \u0442\u043E\u0433\u043E, \u043A\u0430\u043A \u043F\u0440\u043E\u043C\u0435\u0436\u0443\u0442\u043E\u0447\u043D\u044B\u0439 \u0430\u043D\u0430\u043B\u0438\u0437 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u0439 \u0444\u0430\u0437\u044B III \u043F\u043E\u043A\u0430\u0437\u0430\u043B, \u0447\u0442\u043E \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C BBIBP-CorV \u043F\u0440\u043E\u0442\u0438\u0432 \u0438\u043D\u0444\u0435\u043A\u0446\u0438\u0438 COVID-19 \u0441\u043E\u0441\u0442\u0430\u0432\u043B\u044F\u0435\u0442 86%. \u0418 \u0411\u0430\u0445\u0440\u0435\u0439\u043D, \u0438 \u041E\u0410\u042D \u043E\u0434\u043E\u0431\u0440\u0438\u043B\u0438 \u0438\u0441\u043F\u043E\u043B\u044C\u0437\u043E\u0432\u0430\u043D\u0438\u0435 \u0432\u0430\u043A\u0446\u0438\u043D\u044B. \u0412 \u041E\u0410\u042D \u043D\u0435 \u0441\u043E\u043E\u0431\u0449\u0438\u043B\u0438, \u043A\u0430\u043A \u0431\u0443\u0434\u0435\u0442 \u0440\u0430\u0437\u0432\u043E\u0440\u0430\u0447\u0438\u0432\u0430\u0442\u044C\u0441\u044F \u0432\u0430\u043A\u0446\u0438\u043D\u0438\u0440\u043E\u0432\u0430\u043D\u0438\u0435." , "lang" : "ru" } ,      { "type" : "literal", "value" : "BBIBP-CorV, tamb\u00E9m conhecida como a vacina contra COVID-19 da Sinopharm, \u00E9 uma vacina de v\u00EDrus inativado contra COVID-19 desenvolvida pela farmac\u00EAutica chinesa Sinopharm. At\u00E9 o come\u00E7o de mar\u00E7o de 2021, o imunizante estava sendo usado em campanhas de vacina\u00E7\u00E3o em massa de ao menos 15 pa\u00EDses, com a farmac\u00EAutica esperando produzir um bilh\u00E3o de doses em 2021." , "lang" : "pt" } ,      { "type" : "literal", "value" : "\u4F17\u7231\u53EF\u7EF4\uFF08\u4EE3\u53F7\uFF1ABBIBP-CorV \uFF09\u662F\u7531\u4E2D\u56FD\u533B\u836F\u96C6\u56E2\u5317\u4EAC\u751F\u7269\u5236\u54C1\u7814\u7A76\u6240\uFF08BBPI\uFF09\u7814\u53D1\u7684\u4E00\u6B3E2019\u51A0\u72B6\u75C5\u6BD2\u75C5\u75AB\u82D7\uFF0C\u8BE5\u75AB\u82D7\u91C7\u7528\u706D\u6D3BSARS-CoV-2\u75C5\u6BD2\uFF08Vero\u7EC6\u80DE\uFF09\u6280\u672F\uFF0C\u83B7\u5F97\u6709\u4E16\u754C\u536B\u751F\u7EC4\u7EC7\u7D27\u6025\u4F7F\u7528\u8BA4\u8BC1\u3002\u300A\u7F8E\u56FD\u533B\u5B66\u4F1A\u6742\u5FD7\u300B\u520A\u767B\u7684\u7ECF\u8FC7\u540C\u884C\u8BC4\u5BA1\u7684\u2162\u671F\u4E34\u5E8A\u8BD5\u9A8C\u7ED3\u679C\uFF08\u4E8E\u963F\u62C9\u4F2F\u8054\u5408\u914B\u957F\u56FD\u548C\u5DF4\u6797\uFF09\u663E\u793A\uFF0C\u4F17\u7231\u53EF\u7EF4\u5BF9\u9884\u9632\u6709\u75C7\u72B6\u611F\u67D3\u7684\u6709\u6548\u7387\u4E3A78.1%\uFF0C\u5BF9\u9884\u9632\u91CD\u75C7\u75C5\u4F8B\u7684\u6709\u6548\u7387\u4E3A100%\u3002" , "lang" : "zh" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u00E8 un vaccino basato su virus inattivo contro la COVID-19 sviluppato da Sinopharm. BBIBP-CorV \u00E8 simile ai CoronaVac e BBV152, tutti basati su virus inattivato; la somministrazione \u00E8 per iniezione intramuscolare." , "lang" : "it" } ,      { "type" : "literal", "value" : "BBIBP-CorV (auch BIBP-CorV, Covilo oder Hayat-Vax) ist ein COVID-19-Impfstoff des zum chinesischen Staatskonzerns Sinopharm geh\u00F6renden Beijing Institute of Biological Products. BBIBP-CorV ist ein Totimpfstoff. Er wird in verschiedenen L\u00E4ndern in Asien, S\u00FCdamerika, Afrika und Europa eingesetzt." , "lang" : "de" } ,      { "type" : "literal", "value" : "\uC2DC\uB178\uD31C BBIBP-CorV \uCF54\uB85C\uB09819 \uBC31\uC2E0 \uB610\uB294 BBIBP-CorV\uB294 \uC911\uD654\uC778\uBBFC\uACF5\uD654\uAD6D \uC2DC\uB178\uD31C\uC774 \uAC1C\uBC1C\uD55C \uCF54\uB85C\uB09819 \uBC31\uC2E0\uC774\uB2E4. \uC774 \uBC31\uC2E0\uC758 \uB69C\uAED1\uC740 \uC8FC\uD669\uC0C9\uC774\uB2E4." , "lang" : "ko" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u00E4r ett kinesiskt Covid-19-vaccin och ett av tv\u00E5 som utvecklats av vaccinf\u00F6retaget Sinopharm i samarbete med sina dotterf\u00F6retag Beijing Institute of Biological Products respektive Wuhan Institute of Biological Products. B\u00E5da tv\u00E5 \u00E4r baserade p\u00E5 traditionell metodik och bygger p\u00E5 inaktiverat virus. Vaccinet var per december 2020 i fas III-f\u00F6rs\u00F6k i bland andra Argentina, Bahrain, Egypten, Marocko, Pakistan, Peru och F\u00F6renade arabemiraten med fler \u00E4n 60.000 deltagare. Kinesiska myndigheter hade tidigare godk\u00E4nt det f\u00F6r akutanv\u00E4ndning och per november 2020 hade uppemot en miljon kineser f\u00E5tt vaccinet. Per december 2020 hade ocks\u00E5 uppemot 100.000 personer i F\u00F6renade arabemiraten vaccinerats." , "lang" : "sv" } ,      { "type" : "literal", "value" : "BBIBP-CorV adalah salah satu dari dua vaksin COVID-19 yang dikembangkan oleh Sinopharm. Pada Desember 2020, vaksin tersebut berada dalam pengujian Tahap III di Argentina, Bahrain, Mesir, Maroko, Pakistan, Peru, dan Uni Emirat Arab dengan lebih dari 60.000 partisipan. Pada November, sekitar satu juta orang mendapatkan vaksin tersebut melalui program pemakaian darurat Tiongkok." , "lang" : "in" } ,      { "type" : "literal", "value" : "\u0644\u0642\u0627\u062D \u0633\u064A\u0646\u0648\u0641\u0627\u0631\u0645 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Sinopharm vaccine)\u200F \u0628\u0627\u0644\u0627\u0633\u0645 \u0627\u0644\u062A\u062C\u0627\u0631\u064A \u0623\u0648 \u0644\u0642\u0627\u062D BBIBP-CorV \u0628\u0627\u0633\u0645\u0647 \u0627\u0644\u0623\u0635\u0644\u064A\u060C \u0647\u0648 \u0623\u062D\u062F \u0627\u0644\u0644\u0642\u0627\u062D\u064A\u0646 \u0627\u0644\u0645\u0631\u0634\u062D\u064A\u0646 \u0636\u062F \u0645\u0631\u0636 \u0641\u064A\u0631\u0648\u0633 \u0643\u0648\u0631\u0648\u0646\u0627\u060C \u0627\u0644\u0630\u064A\u0646 \u062A\u0639\u0645\u0644 \u0645\u062C\u0645\u0648\u0639\u0629 \u0627\u0644\u0635\u064A\u0646 \u0627\u0644\u0648\u0637\u0646\u064A\u0629 \u0644\u0644\u0635\u0646\u0627\u0639\u0627\u062A \u0627\u0644\u062F\u0648\u0627\u0626\u064A\u0629 \u0639\u0644\u0649 \u062A\u0637\u0648\u064A\u0631\u0647\u0645\u0627 \u0648\u0625\u0646\u062A\u0627\u062C\u0647\u0645\u0627\u060C \u0648\u0647\u0648 \u0645\u062E\u0635\u0635 \u0644\u0644\u0625\u0639\u0637\u0627\u0621 \u0639\u0646 \u0637\u0631\u064A\u0642 \u0627\u0644\u062D\u0642\u0646 \u0627\u0644\u0639\u0636\u0644\u064A. \u0641\u064A 9 \u062F\u064A\u0633\u0645\u0628\u0631 2020\u060C \u0623\u0639\u0644\u0646\u062A \u0627\u0644\u0625\u0645\u0627\u0631\u0627\u062A \u0639\u0646 \u0627\u0644\u062A\u0633\u062C\u064A\u0644 \u0627\u0644\u0631\u0633\u0645\u064A \u0644\u0644\u0642\u0627\u062D \u0633\u064A\u0646\u0648\u0641\u0627\u0631\u0645 \u0628\u0639\u062F \u0623\u0646 \u0623\u0638\u0647\u0631 \u062A\u062D\u0644\u064A\u0644 \u0645\u0624\u0642\u062A \u0644\u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u0645\u0631\u062D\u0644\u0629 \u0627\u0644\u062B\u0627\u0644\u062B\u0629 \u0623\u0646 \u0627\u0644\u0644\u0642\u0627\u062D \u0641\u0639\u0627\u0644 \u0628\u0646\u0633\u0628\u0629 86% \u0636\u062F \u0639\u062F\u0648\u0649 \u0645\u0631\u0636 \u0641\u064A\u0631\u0648\u0633 \u0643\u0648\u0631\u0648\u0646\u0627 2019. \u0648\u0642\u062F \u0645\u0646\u062D\u062A \u0645\u0639 \u0627\u0644\u0628\u062D\u0631\u064A\u0646 \u062A\u0631\u062E\u064A\u0635\u064B\u0627 \u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0627\u0644\u0644\u0642\u0627\u062D\u060C \u0625\u0644\u0627 \u0625\u0646 \u0627\u0644\u0625\u0645\u0627\u0631\u0627\u062A \u0644\u0645 \u062A\u0630\u0643\u0631 \u0643\u064A\u0641 \u0633\u064A\u064F\u0646\u0634\u0631 \u0627\u0644\u0644\u0642\u0627\u062D." , "lang" : "ar" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u2014 \u043E\u0434\u0438\u043D \u0456\u0437 \u0434\u0432\u043E\u0445 \u043A\u0430\u043D\u0434\u0438\u0434\u0430\u0442\u0456\u0432 \u043D\u0430 \u0456\u043D\u0430\u043A\u0442\u0438\u0432\u043E\u0432\u0430\u043D\u0443 \u0432\u0430\u043A\u0446\u0438\u043D\u0443 \u043F\u0440\u043E\u0442\u0438 COVID-19, \u044F\u043A\u0438\u0439 \u0432\u0438\u0440\u043E\u0431\u043B\u044F\u0454\u0442\u044C\u0441\u044F \u043A\u0438\u0442\u0430\u0439\u0441\u044C\u043A\u043E\u044E \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0454\u044E . \u041D\u0430\u043F\u0440\u0438\u043A\u0456\u043D\u0446\u0456 \u0433\u0440\u0443\u0434\u043D\u044F 2020 \u0440\u043E\u043A\u0443 \u0431\u0443\u043B\u043E \u043F\u0440\u043E\u0432\u0435\u0434\u0435\u043D\u043E \u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F III \u0444\u0430\u0437\u0438 \u00ABBBIBP-CorV\u00BB \u0432 \u0410\u0440\u0433\u0435\u043D\u0442\u0438\u043D\u0456, \u0411\u0430\u0445\u0440\u0435\u0439\u043D\u0456, \u0404\u0433\u0438\u043F\u0442\u0456, \u041C\u0430\u0440\u043E\u043A\u043A\u043E, \u041F\u0430\u043A\u0438\u0441\u0442\u0430\u043D\u0456, \u041F\u0435\u0440\u0443 \u0442\u0430 \u041E\u0410\u0415, \u0432 \u044F\u043A\u0438\u0445 \u0432\u0437\u044F\u043B\u0438 \u0443\u0447\u0430\u0441\u0442\u044C \u043F\u043E\u043D\u0430\u0434 60 \u0442\u0438\u0441\u044F\u0447 \u0443\u0447\u0430\u0441\u043D\u0438\u043A\u0456\u0432. \u0421\u0442\u0430\u043D\u043E\u043C \u043D\u0430 \u043B\u044E\u0442\u0438\u0439 2021 \u0440\u043E\u043A\u0443 \u0432\u0430\u043A\u0446\u0438\u043D\u0430 \u00ABBBIBP-CorV\u00BB \u0432\u0438\u043A\u043E\u0440\u0438\u0441\u0442\u043E\u0432\u0443\u0432\u0430\u043B\u0430\u0441\u044F \u0443 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u043B\u044C\u043D\u0438\u0445 \u043A\u0430\u043C\u043F\u0430\u043D\u0456\u044F\u0445 \u0443 \u043D\u0438\u0437\u0446\u0456 \u043A\u0440\u0430\u0457\u043D \u0410\u0437\u0456\u0457, \u0410\u0444\u0440\u0438\u043A\u0438, \u041F\u0456\u0432\u0434\u0435\u043D\u043D\u043E\u0457 \u0410\u043C\u0435\u0440\u0438\u043A\u0438 \u0442\u0430 \u0404\u0432\u0440\u043E\u043F\u0438." , "lang" : "uk" } ] ,    "http://www.w3.org/2000/01/rdf-schema#seeAlso" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Vacunagate" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/List_of_COVID-19_vaccine_authorizations" } ] ,    "http://xmlns.com/foaf/0.1/name" : [ { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "en" } ] ,    "http://xmlns.com/foaf/0.1/depiction" : [ { "type" : "uri", "value" : "http://commons.wikimedia.org/wiki/Special:FilePath/BBIBP-CorV_Vaccination_Certificate.jpg" } ,      { "type" : "uri", "value" : "http://commons.wikimedia.org/wiki/Special:FilePath/Sinopharm_BBIBP-CorV_COVID-19_vaccine_vial_from_Nikli,_Bangladesh.jpg" } ] ,    "http://purl.org/dc/terms/subject" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Chinese_COVID-19_vaccines" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Inactivated_vaccines" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Products_introduced_in_2020" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Clinical_trials" } ] ,    "http://dbpedia.org/ontology/abstract" : [ { "type" : "literal", "value" : "BBIBP-CorV, ook bekend als het Sinopharm-COVID-19-vaccin is een van de twee ge\u00EFnactiveerde COVID-19-vaccins die door zijn ontwikkeld. Eind december 2020 was het in fase III-onderzoek in Argentini\u00EB, Bahrein, Egypte, Marokko, Pakistan, Peru en de Verenigde Arabische Emiraten (VAE) met meer dan 60.000 deelnemers. BBIBP-CorV gebruikt een gelijkaardige technologie als CoronaVac en BBV152, andere ge\u00EFnactiveerde virusvaccins voor COVID-19. Op 9 december maakte de VAE tussentijdse resultaten bekend van fase III-onderzoeken, waaruit bleek dat BBIBP-CorV een werkzaamheid van 86% had tegen COVID-19-infectie. Eind december kondigde Sinopharm aan dat zijn interne analyse een werkzaamheid van 79% aantoonde. Terwijl mRNA-vaccins zoals het Pfizer-BioNTech COVID-19-vaccin en mRNA-1273 een hogere werkzaamheid van meer dan 90% vertoonden, vormen deze vaccins voor sommige landen een uitdaging voor de distributie, aangezien ze diepvriesfaciliteiten en -vrachtwagens nodig hebben. BIBP-CorV kan worden vervoerd en opgeslagen bij normale gekoelde temperaturen. BBIBP-CorV wordt gebruikt in vaccinatiecampagnes door bepaalde landen in Azi\u00EB, Afrika, Zuid-Amerika, en Europa. Sinopharm verwacht in 2021 een miljard doses BBIBP-CorV te produceren. Op 26 maart zei Sinopharm dat er meer dan 80 miljoen doses waren toegediend. Op 7 mei 2021 heeft de Wereldgezondheidsorganisatie (WHO) het Sinopharm-COVID-19-vaccin toegevoegd aan de lijst van vaccins die zijn goedgekeurd voor gebruik in noodgevallen voor de COVID-19 Vaccines Global Access (COVAX)." , "lang" : "nl" } ,      { "type" : "literal", "value" : "BBIBP-CorV adalah salah satu dari dua vaksin COVID-19 yang dikembangkan oleh Sinopharm. Pada Desember 2020, vaksin tersebut berada dalam pengujian Tahap III di Argentina, Bahrain, Mesir, Maroko, Pakistan, Peru, dan Uni Emirat Arab dengan lebih dari 60.000 partisipan. Pada November, sekitar satu juta orang mendapatkan vaksin tersebut melalui program pemakaian darurat Tiongkok." , "lang" : "in" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u00E8 un vaccino basato su virus inattivo contro la COVID-19 sviluppato da Sinopharm. BBIBP-CorV \u00E8 simile ai CoronaVac e BBV152, tutti basati su virus inattivato; la somministrazione \u00E8 per iniezione intramuscolare." , "lang" : "it" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u00E4r ett kinesiskt Covid-19-vaccin och ett av tv\u00E5 som utvecklats av vaccinf\u00F6retaget Sinopharm i samarbete med sina dotterf\u00F6retag Beijing Institute of Biological Products respektive Wuhan Institute of Biological Products. B\u00E5da tv\u00E5 \u00E4r baserade p\u00E5 traditionell metodik och bygger p\u00E5 inaktiverat virus. Vaccinet var per december 2020 i fas III-f\u00F6rs\u00F6k i bland andra Argentina, Bahrain, Egypten, Marocko, Pakistan, Peru och F\u00F6renade arabemiraten med fler \u00E4n 60.000 deltagare. Kinesiska myndigheter hade tidigare godk\u00E4nt det f\u00F6r akutanv\u00E4ndning och per november 2020 hade uppemot en miljon kineser f\u00E5tt vaccinet. Per december 2020 hade ocks\u00E5 uppemot 100.000 personer i F\u00F6renade arabemiraten vaccinerats." , "lang" : "sv" } ,      { "type" : "literal", "value" : "Vakc\u00EDna Sinopharm BIBP proti covidu-19, tak\u00E9 zn\u00E1m\u00E1 jako BBIBP-CorV, vakc\u00EDna Sinopharm COVID-19, nebo BIBP vakc\u00EDna, je jedn\u00EDm ze dvou inaktivovan\u00FDch vakc\u00EDn proti nemoci COVID-19 vyvinut\u00E9 Pekingsk\u00FDm institutem biologick\u00FDch produkt\u016F Sinopharm (n\u011Bkdy ozna\u010Dovan\u00FD jako Pekingsk\u00FD bio-Institut biologick\u00FDch produkt\u016F, co\u017E vede ke dv\u011Bma r\u016Fzn\u00FDm zkratk\u00E1m BBIBP a BIBP pro stejnou vakc\u00EDnu). Pro vakc\u00EDnu byla dokon\u010Dena f\u00E1ze III zkou\u0161ek v Argentin\u011B, Bahrajnu, Egypt\u011B, Maroku, P\u00E1kist\u00E1nu, Peru a Spojen\u00FDch arabsk\u00FDch emir\u00E1tech (SAE) s v\u00EDce ne\u017E 60 000 \u00FA\u010Dastn\u00EDky. BBIBP-CorV sd\u00EDl\u00ED podobnou technologii s CoronaVac a , dal\u0161\u00EDmi inaktivovan\u00FDmi virov\u00FDmi vakc\u00EDnami proti covidu-19. N\u00E1zev jeho produktu je SARS-CoV-2 Vakc\u00EDna (Vero Cell), nezam\u011B\u0148ujte s podobn\u00FDm n\u00E1zvem - CoronaVac. Vz\u00E1jemn\u011B zhodnocen\u00E9 v\u00FDsledky publikovan\u00E9 studie III ve Spojen\u00FDch arabsk\u00FDch emir\u00E1tech a Bahrajnu uk\u00E1zaly, \u017Ee BBIBP-CorV je ze 78,1 % \u00FA\u010Dinn\u00FD proti symptomatick\u00FDm p\u0159\u00EDpad\u016Fm a ze 100 % proti t\u011B\u017Ek\u00FDm p\u0159\u00EDpad\u016Fm (21 p\u0159\u00EDpad\u016F v o\u010Dkovan\u00E9 skupin\u011B oproti 95 p\u0159\u00EDpad\u016Fm ve skupin\u011B s placebem). V prosinci 2020 SAE ji\u017E d\u0159\u00EDve ozn\u00E1mily pr\u016Fb\u011B\u017En\u00E9 v\u00FDsledky ukazuj\u00EDc\u00ED 86 % \u00FA\u010Dinnost. Zat\u00EDmco vakc\u00EDny mRNA, jako jsou vakc\u00EDny Pfizer\u2013BioNtech COVID-19 a vakc\u00EDna Moderna COVID-19, vykazovaly vy\u0161\u0161\u00ED \u00FA\u010Dinnost - p\u0159es 90 %, p\u0159edstavuj\u00ED pro n\u011Bkter\u00E9 zem\u011B probl\u00E9my s distribuc\u00ED, proto\u017Ee vy\u017Eaduj\u00ED mrazic\u00ED za\u0159\u00EDzen\u00ED a n\u00E1kladn\u00ED automobily. BBIBP-CorV lze p\u0159epravovat a skladovat p\u0159i norm\u00E1ln\u00ED teplot\u011B v chladni\u010Dce. BBIBP-CorV je pou\u017E\u00EDv\u00E1n v o\u010Dkovac\u00EDch kampan\u00EDch v n\u011Bkter\u00FDch zem\u00EDch v Asii, Africe, Ji\u017En\u00ED Americe, a Evrop\u011B. Sinopharm o\u010Dek\u00E1v\u00E1, \u017Ee v roce 2021 vyrob\u00ED jednu miliardu d\u00E1vek BBIBP-CorV. Do kv\u011Btna 2021 Sinopharm dodal 200 milion\u016F d\u00E1vek. Dne 7. kv\u011Btna 2021 schv\u00E1lila Sv\u011Btov\u00E1 zdravotnick\u00E1 organizace vakc\u00EDnu pro pou\u017Eit\u00ED v iniciativ\u011B COVAX. Sinopharm podepsal kupn\u00ED smlouvy na 170 milion\u016F d\u00E1vek od COVAX. Dal\u0161\u00ED vakc\u00EDnou s inaktivovan\u00FDm virem vyvinutou spole\u010Dnost\u00ED Sinopharm je WIBP-CorV. O\u010Dkovac\u00ED pr\u016Fkaz BBIBP-CorV (Beijing Institute of Biological Products, ). Vakc\u00EDna se pod\u00E1v\u00E1 intramuskul\u00E1rn\u00ED injekc\u00ED do deltov\u00E9ho svalu . Po\u010D\u00E1te\u010Dn\u00ED k\u00FAra se skl\u00E1d\u00E1 ze dvou d\u00E1vek a neexistuje \u017E\u00E1dn\u00FD d\u016Fkaz, \u017Ee je zapot\u0159eb\u00ED t\u0159et\u00ED posilovac\u00ED d\u00E1vka. Sv\u011Btov\u00E1 zdravotnick\u00E1 organizace (WHO) doporu\u010Duje interval mezi d\u00E1vkami 3 a\u017E 4 t\u00FDdny." , "lang" : "cs" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u2014 \u043E\u0434\u0438\u043D \u0456\u0437 \u0434\u0432\u043E\u0445 \u043A\u0430\u043D\u0434\u0438\u0434\u0430\u0442\u0456\u0432 \u043D\u0430 \u0456\u043D\u0430\u043A\u0442\u0438\u0432\u043E\u0432\u0430\u043D\u0443 \u0432\u0430\u043A\u0446\u0438\u043D\u0443 \u043F\u0440\u043E\u0442\u0438 COVID-19, \u044F\u043A\u0438\u0439 \u0432\u0438\u0440\u043E\u0431\u043B\u044F\u0454\u0442\u044C\u0441\u044F \u043A\u0438\u0442\u0430\u0439\u0441\u044C\u043A\u043E\u044E \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0454\u044E . \u041D\u0430\u043F\u0440\u0438\u043A\u0456\u043D\u0446\u0456 \u0433\u0440\u0443\u0434\u043D\u044F 2020 \u0440\u043E\u043A\u0443 \u0431\u0443\u043B\u043E \u043F\u0440\u043E\u0432\u0435\u0434\u0435\u043D\u043E \u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F III \u0444\u0430\u0437\u0438 \u00ABBBIBP-CorV\u00BB \u0432 \u0410\u0440\u0433\u0435\u043D\u0442\u0438\u043D\u0456, \u0411\u0430\u0445\u0440\u0435\u0439\u043D\u0456, \u0404\u0433\u0438\u043F\u0442\u0456, \u041C\u0430\u0440\u043E\u043A\u043A\u043E, \u041F\u0430\u043A\u0438\u0441\u0442\u0430\u043D\u0456, \u041F\u0435\u0440\u0443 \u0442\u0430 \u041E\u0410\u0415, \u0432 \u044F\u043A\u0438\u0445 \u0432\u0437\u044F\u043B\u0438 \u0443\u0447\u0430\u0441\u0442\u044C \u043F\u043E\u043D\u0430\u0434 60 \u0442\u0438\u0441\u044F\u0447 \u0443\u0447\u0430\u0441\u043D\u0438\u043A\u0456\u0432. 9 \u0433\u0440\u0443\u0434\u043D\u044F \u0432 \u041E\u0410\u0415 \u043E\u0433\u043E\u043B\u043E\u0441\u0438\u043B\u0438 \u043F\u0440\u043E\u043C\u0456\u0436\u043D\u0456 \u0440\u0435\u0437\u0443\u043B\u044C\u0442\u0430\u0442\u0438 III \u0444\u0430\u0437\u0438 \u043A\u043B\u0456\u043D\u0456\u0447\u043D\u043E\u0433\u043E \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F, \u0437\u0433\u0456\u0434\u043D\u043E \u044F\u043A\u0438\u0445 \u00ABBBIBP-CorV\u00BB \u043C\u0430\u0454 86 % \u0435\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u0456\u0441\u0442\u044C \u043F\u0440\u043E\u0442\u0438 COVID-19. \u041D\u0430\u043F\u0440\u0438\u043A\u0456\u043D\u0446\u0456 \u0433\u0440\u0443\u0434\u043D\u044F \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u044F \u00ABSinopharm\u00BB \u043F\u043E\u0432\u0456\u0434\u043E\u043C\u0438\u043B\u0430, \u0449\u043E \u0457\u0457 \u0432\u043D\u0443\u0442\u0440\u0456\u0448\u043D\u0456\u0439 \u0430\u043D\u0430\u043B\u0456\u0437 \u043E\u0446\u0456\u043D\u0438\u0432 \u0435\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u0456\u0441\u0442\u044C \u0432\u0430\u043A\u0446\u0438\u043D\u0438 \u0443 79 %. \u0425\u043E\u0447\u0430 \u043C\u0420\u041D\u041A-\u0432\u0430\u043A\u0446\u0438\u043D\u0438 \u043F\u0440\u043E\u0442\u0438 COVID-19, \u0437\u043E\u043A\u0440\u0435\u043C\u0430 \u0442\u043E\u0437\u0456\u043D\u0430\u043C\u0435\u0440\u0430\u043D \u0442\u0430 \u00ABModerna\u00BB, \u043F\u043E\u043A\u0430\u0437\u0430\u043B\u0438 \u0432\u0438\u0449\u0443 \u0435\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u0456\u0441\u0442\u044C \u2014 \u0431\u043B\u0438\u0437\u044C\u043A\u043E 90 %, \u043F\u0440\u043E\u0442\u0435 \u0434\u043B\u044F \u0434\u0435\u044F\u043A\u0438\u0445 \u043A\u0440\u0430\u0457\u043D \u043C\u043E\u0436\u0443\u0442\u044C \u0432\u0438\u043D\u0438\u043A\u043D\u0443\u0442\u0438 \u0442\u0440\u0443\u0434\u043D\u043E\u0449\u0456 \u043F\u0440\u0438 \u0457\u0445 \u0442\u0440\u0430\u043D\u0441\u043F\u043E\u0440\u0442\u0443\u0432\u0430\u043D\u043D\u0456, \u043E\u0441\u043A\u0456\u043B\u044C\u043A\u0438 \u0457\u043C \u043F\u043E\u0442\u0440\u0456\u0431\u043D\u0456 \u0443\u0441\u0442\u0430\u043D\u043E\u0432\u043A\u0438 \u0434\u043B\u044F \u0433\u043B\u0438\u0431\u043E\u043A\u043E\u0433\u043E \u0437\u0430\u043C\u043E\u0440\u043E\u0436\u0443\u0432\u0430\u043D\u043D\u044F \u0442\u0430 \u0432\u0430\u043D\u0442\u0430\u0436\u0456\u0432\u043A\u0438. \u00ABBIBP-CorV\u00BB \u043C\u043E\u0436\u043D\u0430 \u0442\u0440\u0430\u043D\u0441\u043F\u043E\u0440\u0442\u0443\u0432\u0430\u0442\u0438 \u0442\u0430 \u0437\u0431\u0435\u0440\u0456\u0433\u0430\u0442\u0438 \u043F\u0440\u0438 \u043D\u0435\u0437\u043D\u0430\u0447\u043D\u043E\u043C\u0443 \u043E\u0445\u043E\u043B\u043E\u0434\u0436\u0435\u043D\u043D\u0456. \u0422\u0435\u0445\u043D\u043E\u043B\u043E\u0433\u0456\u044F \u0432\u0438\u0440\u043E\u0431\u043D\u0438\u0446\u0442\u0432\u0430 \u00ABBBIBP-CorV\u00BB \u043F\u043E\u0434\u0456\u0431\u043D\u0430 \u043D\u0430 \u0442\u0435\u0445\u043D\u043E\u043B\u043E\u0433\u0456\u044E \u0432\u0438\u0440\u043E\u0431\u043D\u0438\u0446\u0442\u0432\u0430 \u0456\u043D\u0448\u0438\u0445 \u0456\u043D\u0430\u043A\u0442\u0438\u0432\u043E\u0432\u0430\u043D\u0438\u0445 \u0432\u0430\u043A\u0446\u0438\u043D \u043F\u0440\u043E\u0442\u0438 COVID-19, \u0437\u043E\u043A\u0440\u0435\u043C\u0430 \u00ABCoronaVac\u00BB \u0442\u0430 \u00ABBBV152\u00BB, \u044F\u043A\u0456 \u0442\u0430\u043A\u043E\u0436 \u043F\u0440\u043E\u0445\u043E\u0434\u044F\u0442\u044C \u0406\u0406\u0406 \u0444\u0430\u0437\u0443 \u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0438\u0445 \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u044C. \u0412\u0456\u0434\u0441\u0443\u0442\u043D\u0456\u0441\u0442\u044C \u0432\u0456\u0434\u043A\u0440\u0438\u0442\u0438\u0445 \u0434\u0430\u043D\u0438\u0445, \u043F\u043E\u0432'\u044F\u0437\u0430\u043D\u0438\u0445 \u0437 \u00ABBBIBP-CorV\u00BB, \u043C\u043E\u0436\u0435 \u0441\u043F\u0440\u0438\u0447\u0438\u043D\u0438\u0442\u0438 \u043E\u0431\u043C\u0435\u0436\u0435\u043D\u043D\u044F \u0434\u043B\u044F \u00ABSinopharm\u00BB \u0443 \u043F\u043E\u0441\u0442\u0430\u0447\u0430\u043D\u043D\u0456 \u0432\u0430\u043A\u0446\u0438\u043D\u0438 \u0434\u043E \u041A\u0438\u0442\u0430\u044E \u0442\u0430 \u043B\u0438\u0448\u0435 \u0434\u043E \u043A\u0456\u043B\u044C\u043A\u043E\u0445 \u0456\u043D\u0448\u0438\u0445 \u043A\u0440\u0430\u0457\u043D. \u0421\u0442\u0430\u043D\u043E\u043C \u043D\u0430 \u043B\u044E\u0442\u0438\u0439 2021 \u0440\u043E\u043A\u0443 \u0432\u0430\u043A\u0446\u0438\u043D\u0430 \u00ABBBIBP-CorV\u00BB \u0432\u0438\u043A\u043E\u0440\u0438\u0441\u0442\u043E\u0432\u0443\u0432\u0430\u043B\u0430\u0441\u044F \u0443 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u043B\u044C\u043D\u0438\u0445 \u043A\u0430\u043C\u043F\u0430\u043D\u0456\u044F\u0445 \u0443 \u043D\u0438\u0437\u0446\u0456 \u043A\u0440\u0430\u0457\u043D \u0410\u0437\u0456\u0457, \u0410\u0444\u0440\u0438\u043A\u0438, \u041F\u0456\u0432\u0434\u0435\u043D\u043D\u043E\u0457 \u0410\u043C\u0435\u0440\u0438\u043A\u0438 \u0442\u0430 \u0404\u0432\u0440\u043E\u043F\u0438." , "lang" : "uk" } ,      { "type" : "literal", "value" : "BBIBP-CorV est l'un des deux vaccins \u00E0 virus inactiv\u00E9 contre la COVID-19 con\u00E7u par la soci\u00E9t\u00E9 chinoise Sinopharm. Il est approuv\u00E9 par l'OMS depuis le 10 mai 2021 (autorisation d'utilisation d'urgence) et est utilis\u00E9 dans 60 pays dont la Chine, les \u00C9mirats arabes unis, le Maroc, l'Alg\u00E9rie, l'Argentine, le Bahrein, le P\u00E9rou, l'\u00C9gypte, le Kazakhstan, le S\u00E9n\u00E9gal et le Nigeria." , "lang" : "fr" } ,      { "type" : "literal", "value" : "\uC2DC\uB178\uD31C BBIBP-CorV \uCF54\uB85C\uB09819 \uBC31\uC2E0 \uB610\uB294 BBIBP-CorV\uB294 \uC911\uD654\uC778\uBBFC\uACF5\uD654\uAD6D \uC2DC\uB178\uD31C\uC774 \uAC1C\uBC1C\uD55C \uCF54\uB85C\uB09819 \uBC31\uC2E0\uC774\uB2E4. \uC774 \uBC31\uC2E0\uC758 \uB69C\uAED1\uC740 \uC8FC\uD669\uC0C9\uC774\uB2E4." , "lang" : "ko" } ,      { "type" : "literal", "value" : "La vacuna de Sinopharm contra la COVID-19 (de nombre en clave BBIBP-CorV) conocida a veces como Vero Cell o Sinopharm, es una vacuna contra la COVID-19 de virus inactivado, desarrollada por Sinopharm (China).\u200B La vacuna complet\u00F3 los ensayos cl\u00EDnicos de fase III en los Emiratos \u00C1rabes Unidos, Argentina, Bar\u00E9in, Egipto, Marruecos, Pakist\u00E1n y Per\u00FA, con m\u00E1s de 60 000 personas.\u200B\u200B En noviembre de 2020, alrededor de un mill\u00F3n de personas recibieron la vacuna a trav\u00E9s del programa de uso de emergencia de China.\u200B\u200B En diciembre de 2020, 100 000 personas en los Emiratos \u00C1rabes Unidos, recibieron la vacuna como parte de un programa voluntario.\u200B El 9 de diciembre de 2020, la vacuna obtuvo el registro oficial en los Emiratos \u00C1rabes Unidos, despu\u00E9s de que un an\u00E1lisis intermedio de los ensayos de fase III mostrara que BBIBP-CorV ten\u00EDa una eficacia del 86% contra la infecci\u00F3n por COVID-19.\u200B Tanto Bar\u00E9in como los Emiratos \u00C1rabes Unidos han aprobado el uso de la vacuna.\u200B \u200B Los Emiratos \u00C1rabes Unidos no dijeron c\u00F3mo se implementar\u00EDa la vacuna.\u200B BBIBP-CorV comparte una tecnolog\u00EDa similar con CoronaVac y Covaxin, otras vacunas de virus inactivados para COVID-19.\u200B Su nombre de producto es Vacuna contra el SARS-CoV-2 (Vero Cell),\u200B\u200B que no debe confundirse con el nombre de producto similar de CoronaVac.\u200B\u200B BBIBP-CorV se est\u00E1 utilizando en campa\u00F1as de vacunaci\u00F3n en ciertos pa\u00EDses de Asia,\u200B\u200B\u200B \u00C1frica,\u200B\u200B\u200B Am\u00E9rica del Sur,\u200B\u200B\u200B y Europa.\u200B\u200B\u200B Sinopharm espera producir mil millones de dosis de BBIBP-CorV en 2021.\u200B El 7 de mayo de 2021, la Organizaci\u00F3n Mundial de la Salud aprob\u00F3 la vacuna para su uso en COVAX.\u200B\u200B" , "lang" : "es" } ,      { "type" : "literal", "value" : "\u0644\u0642\u0627\u062D \u0633\u064A\u0646\u0648\u0641\u0627\u0631\u0645 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Sinopharm vaccine)\u200F \u0628\u0627\u0644\u0627\u0633\u0645 \u0627\u0644\u062A\u062C\u0627\u0631\u064A \u0623\u0648 \u0644\u0642\u0627\u062D BBIBP-CorV \u0628\u0627\u0633\u0645\u0647 \u0627\u0644\u0623\u0635\u0644\u064A\u060C \u0647\u0648 \u0623\u062D\u062F \u0627\u0644\u0644\u0642\u0627\u062D\u064A\u0646 \u0627\u0644\u0645\u0631\u0634\u062D\u064A\u0646 \u0636\u062F \u0645\u0631\u0636 \u0641\u064A\u0631\u0648\u0633 \u0643\u0648\u0631\u0648\u0646\u0627\u060C \u0627\u0644\u0630\u064A\u0646 \u062A\u0639\u0645\u0644 \u0645\u062C\u0645\u0648\u0639\u0629 \u0627\u0644\u0635\u064A\u0646 \u0627\u0644\u0648\u0637\u0646\u064A\u0629 \u0644\u0644\u0635\u0646\u0627\u0639\u0627\u062A \u0627\u0644\u062F\u0648\u0627\u0626\u064A\u0629 \u0639\u0644\u0649 \u062A\u0637\u0648\u064A\u0631\u0647\u0645\u0627 \u0648\u0625\u0646\u062A\u0627\u062C\u0647\u0645\u0627\u060C \u0648\u0647\u0648 \u0645\u062E\u0635\u0635 \u0644\u0644\u0625\u0639\u0637\u0627\u0621 \u0639\u0646 \u0637\u0631\u064A\u0642 \u0627\u0644\u062D\u0642\u0646 \u0627\u0644\u0639\u0636\u0644\u064A. \u0627\u0639\u062A\u0628\u0627\u0631\u064B\u0627 \u0645\u0646 \u062F\u064A\u0633\u0645\u0628\u0631 2020\u060C \u062F\u062E\u0644 \u0627\u0644\u0644\u0642\u0627\u062D \u0627\u0644\u0645\u0631\u062D\u0644\u0629 \u0627\u0644\u062B\u0627\u0644\u062B\u0629 \u0645\u0646 \u0627\u0644\u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064A\u0631\u064A\u0629 \u0641\u064A \u0643\u0644 \u0645\u0646: \u0627\u0644\u0623\u0631\u062C\u0646\u062A\u064A\u0646 \u0648\u0627\u0644\u0628\u062D\u0631\u064A\u0646 \u0648\u0645\u0635\u0631 \u0648\u0627\u0644\u0645\u063A\u0631\u0628 \u0648\u0628\u0627\u0643\u0633\u062A\u0627\u0646 \u0648\u0628\u064A\u0631\u0648 \u0648\u0627\u0644\u0625\u0645\u0627\u0631\u0627\u062A \u0627\u0644\u0639\u0631\u0628\u064A\u0629 \u0627\u0644\u0645\u062A\u062D\u062F\u0629 \u0645\u0639 \u0623\u0643\u062B\u0631 \u0645\u0646 60000 \u0634\u062E\u0635. \u062D\u062A\u0649 \u0646\u0648\u0641\u0645\u0628\u0631 2020\u060C \u0643\u0627\u0646 \u0645\u0627 \u064A\u0642\u0631\u0628 \u0645\u0646 \u0645\u0644\u064A\u0648\u0646 \u0634\u062E\u0635 \u0642\u062F \u062A\u0644\u0642\u0648\u0627 \u0627\u0644\u0644\u0642\u0627\u062D \u0645\u0646 \u062E\u0644\u0627\u0644 \u0628\u0631\u0646\u0627\u0645\u062C \u0627\u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0627\u0644\u0637\u0627\u0631\u0626 \u0628\u0627\u0644\u0635\u064A\u0646. \u0628\u062D\u0644\u0648\u0644 \u062F\u064A\u0633\u0645\u0628\u0631 2020\u060C \u062A\u0644\u0642\u0649 \u0645\u0627 \u064A\u0642\u0631\u0628 \u0645\u0646 100,000 \u0634\u062E\u0635 \u0641\u064A \u0627\u0644\u0625\u0645\u0627\u0631\u0627\u062A \u0627\u0644\u0639\u0631\u0628\u064A\u0629 \u0627\u0644\u0645\u062A\u062D\u062F\u0629 \u0627\u0644\u0644\u0642\u0627\u062D \u0643\u062C\u0632\u0621 \u0645\u0646 \u0628\u0631\u0646\u0627\u0645\u062C \u062A\u0637\u0648\u0639\u064A. \u0641\u064A 9 \u062F\u064A\u0633\u0645\u0628\u0631 2020\u060C \u0623\u0639\u0644\u0646\u062A \u0627\u0644\u0625\u0645\u0627\u0631\u0627\u062A \u0639\u0646 \u0627\u0644\u062A\u0633\u062C\u064A\u0644 \u0627\u0644\u0631\u0633\u0645\u064A \u0644\u0644\u0642\u0627\u062D \u0633\u064A\u0646\u0648\u0641\u0627\u0631\u0645 \u0628\u0639\u062F \u0623\u0646 \u0623\u0638\u0647\u0631 \u062A\u062D\u0644\u064A\u0644 \u0645\u0624\u0642\u062A \u0644\u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u0645\u0631\u062D\u0644\u0629 \u0627\u0644\u062B\u0627\u0644\u062B\u0629 \u0623\u0646 \u0627\u0644\u0644\u0642\u0627\u062D \u0641\u0639\u0627\u0644 \u0628\u0646\u0633\u0628\u0629 86% \u0636\u062F \u0639\u062F\u0648\u0649 \u0645\u0631\u0636 \u0641\u064A\u0631\u0648\u0633 \u0643\u0648\u0631\u0648\u0646\u0627 2019. \u0648\u0642\u062F \u0645\u0646\u062D\u062A \u0645\u0639 \u0627\u0644\u0628\u062D\u0631\u064A\u0646 \u062A\u0631\u062E\u064A\u0635\u064B\u0627 \u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0627\u0644\u0644\u0642\u0627\u062D\u060C \u0625\u0644\u0627 \u0625\u0646 \u0627\u0644\u0625\u0645\u0627\u0631\u0627\u062A \u0644\u0645 \u062A\u0630\u0643\u0631 \u0643\u064A\u0641 \u0633\u064A\u064F\u0646\u0634\u0631 \u0627\u0644\u0644\u0642\u0627\u062D. \u0641\u064A 12 \u062F\u064A\u0633\u0645\u0628\u0631 2020\u060C \u0623\u0648\u0642\u0641\u062A \u0628\u064A\u0631\u0648 \u0627\u0644\u062A\u062C\u0627\u0631\u0628 \u0639\u0644\u0649 \u0644\u0642\u0627\u062D \u0633\u064A\u0646\u0648\u0641\u0627\u0631\u0645 \u0644\u0644\u062A\u062D\u0642\u064A\u0642 \u0641\u064A \u062D\u062F\u062B \u0636\u0627\u0631 \u0648\u0642\u0639 \u0645\u0639 \u0623\u062D\u062F \u0627\u0644\u0645\u062A\u0637\u0648\u0639\u064A\u0646 \u0642\u0628\u0644 \u0623\u0646 \u062A\u0639\u064A\u062F \u0627\u0633\u062A\u0626\u0646\u0627\u0641 \u0627\u0644\u062A\u062C\u0627\u0631\u0628 \u0641\u064A 16 \u062F\u064A\u0633\u0645\u0628\u0631. \u064A\u0633\u062A\u062E\u062F\u0645 \u0644\u0642\u0627\u062D BBIBP-CorV \u062A\u0642\u0646\u064A\u0629 \u0645\u0634\u0627\u0628\u0647\u0629 \u0648\u0623\u0643\u062B\u0631 \u062A\u0642\u0644\u064A\u062F\u064A\u0629 \u0643\u0645\u0627 \u0641\u064A \u0643\u0648\u0631\u0648\u0646\u0627\u0641\u0627\u0643 \u0648BBV152 \u0648\u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0623\u062E\u0631\u0649 \u0627\u0644\u062A\u064A \u064A\u062C\u0631\u064A \u062A\u0637\u0648\u064A\u0631\u0647\u0627 \u0641\u064A \u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u0645\u0631\u062D\u0644\u0629 \u0627\u0644\u062B\u0627\u0644\u062B\u0629. \u0637\u064F\u0628\u0642\u062A \u0645\u062B\u0644 \u0647\u0630\u0647 \u0627\u0644\u062A\u0642\u0646\u064A\u0629 \u0628\u0646\u062C\u0627\u062D \u0641\u064A \u0627\u0644\u0639\u062F\u064A\u062F \u0645\u0646 \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0639\u0631\u0648\u0641\u0629 \u0645\u062B\u0644 \u0644\u0642\u0627\u062D \u062F\u0627\u0621 \u0627\u0644\u0643\u0644\u0628\u060C \u0648\u0644\u0643\u0646 \u0646\u0642\u0635 \u0627\u0644\u0628\u064A\u0627\u0646\u0627\u062A \u0627\u0644\u0639\u0627\u0645\u0629 \u0627\u0644\u0645\u062A\u0639\u0644\u0642\u0629 \u0628\u0640 BBIBP-CorV \u064A\u0645\u0643\u0646 \u0623\u0646 \u064A\u062D\u062F \u0645\u0646 \u062A\u0648\u0632\u064A\u0639 \u0627\u0644\u0644\u0642\u0627\u062D \u0641\u064A \u0645\u062C\u0645\u0648\u0639\u0629 \u0645\u062A\u0646\u0648\u0639\u0629 \u0645\u0646 \u0627\u0644\u0628\u0644\u062F\u0627\u0646 \u0627\u0644\u0623\u062E\u0631\u0649." , "lang" : "ar" } ,      { "type" : "literal", "value" : "\u4F17\u7231\u53EF\u7EF4\uFF08\u4EE3\u53F7\uFF1ABBIBP-CorV \uFF09\u662F\u7531\u4E2D\u56FD\u533B\u836F\u96C6\u56E2\u5317\u4EAC\u751F\u7269\u5236\u54C1\u7814\u7A76\u6240\uFF08BBPI\uFF09\u7814\u53D1\u7684\u4E00\u6B3E2019\u51A0\u72B6\u75C5\u6BD2\u75C5\u75AB\u82D7\uFF0C\u8BE5\u75AB\u82D7\u91C7\u7528\u706D\u6D3BSARS-CoV-2\u75C5\u6BD2\uFF08Vero\u7EC6\u80DE\uFF09\u6280\u672F\uFF0C\u83B7\u5F97\u6709\u4E16\u754C\u536B\u751F\u7EC4\u7EC7\u7D27\u6025\u4F7F\u7528\u8BA4\u8BC1\u3002\u300A\u7F8E\u56FD\u533B\u5B66\u4F1A\u6742\u5FD7\u300B\u520A\u767B\u7684\u7ECF\u8FC7\u540C\u884C\u8BC4\u5BA1\u7684\u2162\u671F\u4E34\u5E8A\u8BD5\u9A8C\u7ED3\u679C\uFF08\u4E8E\u963F\u62C9\u4F2F\u8054\u5408\u914B\u957F\u56FD\u548C\u5DF4\u6797\uFF09\u663E\u793A\uFF0C\u4F17\u7231\u53EF\u7EF4\u5BF9\u9884\u9632\u6709\u75C7\u72B6\u611F\u67D3\u7684\u6709\u6548\u7387\u4E3A78.1%\uFF0C\u5BF9\u9884\u9632\u91CD\u75C7\u75C5\u4F8B\u7684\u6709\u6548\u7387\u4E3A100%\u3002" , "lang" : "zh" } ,      { "type" : "literal", "value" : "BBIBP-CorV, tamb\u00E9m conhecida como a vacina contra COVID-19 da Sinopharm, \u00E9 uma vacina de v\u00EDrus inativado contra COVID-19 desenvolvida pela farmac\u00EAutica chinesa Sinopharm. At\u00E9 o come\u00E7o de mar\u00E7o de 2021, o imunizante estava sendo usado em campanhas de vacina\u00E7\u00E3o em massa de ao menos 15 pa\u00EDses, com a farmac\u00EAutica esperando produzir um bilh\u00E3o de doses em 2021. A BBIBP-CorV tem um tecnologia semelhante a CoronaVac e BBV152 - outras vacinas de v\u00EDrus inativado. O imunizante passa por testes de fase III na Argentina, Peru, Paquist\u00E3o, Emirados \u00C1rabes Unidos, Bar\u00E9m, Egito, Marrocos, e envolve mais de 60 000 volunt\u00E1rios. Em 9 de dezembro de 2020, os Emirados \u00C1rabes anunciaram que, baseados em resultados interinos, a vacina possu\u00EDa uma efic\u00E1cia de 86% na preven\u00E7\u00E3o de infec\u00E7\u00F5es por COVID-19. No fim do mesmo m\u00EAs, a Sinopharm anunciou uma efic\u00E1cia de 79%, tendo por base sua an\u00E1lise interina envolvendo outros pa\u00EDses. No entanto, h\u00E1 cr\u00EDticas por parte de especialistas quanto \u00E0 falta de transpar\u00EAncia na divulga\u00E7\u00E3o dos dados de efic\u00E1cia e seguran\u00E7a." , "lang" : "pt" } ,      { "type" : "literal", "value" : "La vakcino kontra\u016D la kronvirusa malsano de 2019 de Sinopharm BIBP, anka\u016D nomita BBIBP-CorV, la vakcino kontra\u016D la kronvirusa malsano de 2019 de Sinopharm, a\u016D vakcino BIBP, estas unu el du vakcinoj kontra\u016D la kronvirusa malsano de 2019 de malaktivigitaj virusoj, kiujn kreis la Instituto de Biologiaj Produktoj de Pekino de Sinopharm (BIBP a\u016D BBIBP). \u011Ci finis triafazajn provojn en Argentino, Barejno, Egiptio, Maroko, Pakistano, Peruo, kaj la Unui\u011Dintaj Arabaj Emirlandoj (UAE) kun pli ol 60 000 partoprenantoj. BBIBP-CorV uzas similan teknologion kiel CoronaVac kaj Covaxin, aliaj vakcinoj de malaktivigitaj virusoj kontra\u016D la kronvirusa malsano de 2019. \u011Cia produkta nomo estas Vakcino SARS-CoV-2 (Vero Cell), kvankam CoronaVac havas vakcinon kun simila nomo. Rezultoj eldonitaj en JAMA de triafazaj provoj en UAE kaj Barejno montris, ke BBIBP-CorV havas efikecon je 78.1% kontra\u016D simptomhavaj kazoj kaj 100% kontra\u016D severaj kazoj (21 kazoj en vakcinhava grupo kontra\u016D 95 kazoj en placeba grupo). En decembro 2020, la UAE anta\u016De anoncis provizorajn rezultojn montrantajn efikecon de 86%. Kvankam vakcinoj de mRNA, kiel la vakcino kontra\u016D la kronvirusa malsano de 2019 de Pfizer\u2013BioNTech kaj la vakcino kontra\u016D la kronvirusa malsano de Moderna, montris pli altan efikecon de pli ol 90%, ili ne facile uzi\u011Das en iuj landoj, \u0109ar ili bezonas malvarmegajn stokejojn kaj veturilojn. BBIBP-CorV povas transporti\u011Di kaj stoki\u011Di je normalaj fridujaj temperaturoj. Kelkaj landoj en Azio, Afriko, Sudameriko, kaj E\u016Dropo uzas la vakcinon BBIBP-CorV. Sinopharm intencas produkti unu miliardon da dozoj de BBIBP-CorV en 2021. \u011Cis majo, Sinopharm estis provizinta 200 milionojn da dozoj. Je la 7a de majo 2021, la Monda Organiza\u0135o pri Sano (MOS) aprobis la vakcinon por uzo en COVAX. Sinopharm subskribis a\u0109etajn interkonsentojn por 170 milionoj da dozoj de COVAX. La alia vakcino de malaktivigita viruso kreita de Sinopharm estas WIBP-CorV." , "lang" : "eo" } ,      { "type" : "literal", "value" : "The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine (Vero Cell), not to be confused with the similar product name of CoronaVac. Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group). In December 2020, the UAE previously announced interim results showing 86% efficacy. While mRNA vaccines like the Pfizer\u2013BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. The BIBP vaccine could be transported and stored at normal refrigerated temperatures. The vaccine is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. Sinopharm expects to produce one billion doses of the vaccine in 2021. By May, Sinopharm had supplied 200 million doses. On 7 May 2021, the World Health Organization approved the BIBP vaccine for use in COVAX. Sinopharm has signed purchase agreements for 170 million doses from COVAX. The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine." , "lang" : "en" } ,      { "type" : "literal", "value" : "BBIBP-CorV (auch BIBP-CorV, Covilo oder Hayat-Vax) ist ein COVID-19-Impfstoff des zum chinesischen Staatskonzerns Sinopharm geh\u00F6renden Beijing Institute of Biological Products. BBIBP-CorV ist ein Totimpfstoff. Er wird in verschiedenen L\u00E4ndern in Asien, S\u00FCdamerika, Afrika und Europa eingesetzt." , "lang" : "de" } ,      { "type" : "literal", "value" : "\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0COVID-19\u30EF\u30AF\u30C1\u30F3\uFF08\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u30B3\u30D3\u30C3\u30C919\u30EF\u30AF\u30C1\u30F3\uFF09\u306F\u3001BBIBP-CorV\u3068\u3082\u547C\u3070\u308C\u3001\u4E2D\u56FD\u306E\u56FD\u55B6\u4F01\u696D\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u793E\u304C\u958B\u767A\u3057\u305F2\u7A2E\u985E\u306E\u4E0D\u6D3B\u5316\u30A6\u30A4\u30EB\u30B9COVID-19\u30EF\u30AF\u30C1\u30F3\u306E\u3046\u3061\u306E1\u3064\u3067\u3042\u308B\u30022020\u5E7412\u6708\u4E0B\u65EC\u3001\u30A2\u30EB\u30BC\u30F3\u30C1\u30F3\u3001\u30D0\u30FC\u30EC\u30FC\u30F3\u3001\u30A8\u30B8\u30D7\u30C8\u3001\u30E2\u30ED\u30C3\u30B3\u3001\u30D1\u30AD\u30B9\u30BF\u30F3\u3001\u30DA\u30EB\u30FC\u3001\u30A2\u30E9\u30D6\u9996\u9577\u56FD\u9023\u90A6\uFF08UAE\uFF09\u3067\u7B2CIII\u76F8\u81E8\u5E8A\u8A66\u9A13\u304C\u884C\u308F\u308C\u300160,000\u4EBA\u4EE5\u4E0A\u304C\u53C2\u52A0\u3057\u305F\u3002 12\u67089\u65E5\u3001UAE\u306F\u3001BBIBP-CorV\u304CCOVID-19\u611F\u67D3\u75C7\u306B\u5BFE\u3057\u306686\uFF05\u306E\u6709\u52B9\u6027\u3092\u793A\u3057\u305F\u7B2CIII\u76F8\u8A66\u9A13\u306E\u4E2D\u9593\u7D50\u679C\u3092\u767A\u8868\u3057\u300112\u6708\u4E0B\u65EC\u306B\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u306F\u3001\u5185\u90E8\u5206\u6790\u306779\uFF05\u306E\u6709\u52B9\u6027\u304C\u793A\u3055\u308C\u305F\u3068\u767A\u8868\u3057\u305F\u30022021\u5E745\u6708\u306B\u306F\u30EF\u30AF\u30C1\u30F3\u3092\u627F\u8A8D\u3057\u305F\u4E16\u754C\u4FDD\u5065\u6A5F\u95A2\uFF08WHO\uFF09\u304C\u6709\u52B9\u6027\u309279\uFF05\u3068\u63A8\u5B9A\u3057\u305F\u3002\u30D5\u30A1\u30A4\u30B6\u30FC-\u30D0\u30A4\u30AA\u30F3\u30C6\u30C3\u30AFCOVID-19\u30EF\u30AF\u30C1\u30F3\u3084\u30E2\u30C7\u30EB\u30CAmRNA-1273\u306E\u3088\u3046\u306AmRNA\u30EF\u30AF\u30C1\u30F3\u306F90%\u4EE5\u4E0A\u306E\u9AD8\u3044\u6709\u52B9\u6027\u3092\u793A\u3057\u3066\u3044\u308B\u304C\u3001\u3053\u308C\u3089\u306E\u30EF\u30AF\u30C1\u30F3\u306F\u8D85\u4F4E\u6E29\u51B7\u51CD\u5EAB\u3068\u8F38\u9001\u8ECA\u3092\u5FC5\u8981\u3068\u3059\u308B\u305F\u3081\u3001\u4E00\u90E8\u306E\u56FD\u3067\u306F\u6D41\u901A\u4E0A\u306E\u8AB2\u984C\u3068\u306A\u3063\u3066\u3044\u308B\u3002BIBP-CorV\u306F\u3001\u901A\u5E38\u306E\u51B7\u8535\u6E29\u5EA6\u3067\u8F38\u9001\u30FB\u4FDD\u5B58\u304C\u53EF\u80FD\u3067\u3042\u308B\u3002 BBIBP-CorV\u306F\u3001\u7B2CIII\u76F8\u8A66\u9A13\u3067\u958B\u767A\u304C\u9032\u3081\u3089\u308C\u3066\u3044\u308BCOVID-19\u7528\u4E0D\u6D3B\u5316\u30A6\u30A4\u30EB\u30B9\u30EF\u30AF\u30C1\u30F3\u3067\u3042\u308BCoronaVac\u3084BBV152\u3068\u540C\u69D8\u306E\u3001\u3088\u308A\u4F1D\u7D71\u7684\u306A\u6280\u8853\u3092\u5171\u6709\u3057\u3066\u3044\u308B\u3002 BBIBP-CorV\u306F\u3001\u30A2\u30B8\u30A2\u3001\u30A2\u30D5\u30EA\u30AB\u3001\u5357\u7C73\u3001\u304A\u3088\u3073\u6B27\u5DDE\u306E\u4E00\u90E8\u306E\u56FD\u3067\u306F\u30EF\u30AF\u30C1\u30F3\u63A5\u7A2E\u30AD\u30E3\u30F3\u30DA\u30FC\u30F3\u306B\u4F7F\u7528\u3055\u308C\u3066\u3044\u305F\u3002\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u306F\u30012021\u5E74\u306B10\u5104\u7528\u91CF\u5206\u306EBBIBP-CorV\u306E\u751F\u7523\u3092\u898B\u8FBC\u3093\u3067\u3044\u308B\u3002\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u306B\u3088\u308B\u3068\u30012\u670821\u65E5\u307E\u3067\u306B\u5408\u8A08\u30674,300\u4E07\u56DE\u4EE5\u4E0A\u306E\u30EF\u30AF\u30C1\u30F3\u304C\u63A5\u7A2E\u3055\u308C\u305F\u3068\u3044\u3046\u3002 BBIBP-CorV\u306F\u30012021\u5E745\u67087\u65E5\u306BWHO\u304C\u6B27\u7C73\u4EE5\u5916\u3067\u306F\u521D\u3081\u3066\u7DCA\u6025\u4F7F\u7528\u3092\u627F\u8A8D\u3057\u305F\u30EF\u30AF\u30C1\u30F3\u3068\u306A\u3063\u3066\u304A\u308A\u3001\u65B0\u578B\u30B3\u30ED\u30CA\u30EF\u30AF\u30C1\u30F3\u3078\u306E\u516C\u5E73\u306A\u30A2\u30AF\u30BB\u30B9\u3092\u76EE\u6307\u3059\u56FD\u969B\u7684\u306A\u67A0\u7D44\u307F\u300CCOVAX\u300D\u306B\u3082\u4F9B\u7D66\u3055\u308C\u3066\u3044\u308B\u304C\u3001\u516C\u7528\u30C7\u30FC\u30BF\u304C\u4E0D\u8DB3\u3057\u3066\u3044\u308B\u305F\u3081\u3001\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0\u306F\u4E2D\u56FD\u56FD\u5185\u304A\u3088\u3073\u4ED6\u306E\u3055\u307E\u3056\u307E\u306A\u56FD\u3067\u30EF\u30AF\u30C1\u30F3\u306E\u914D\u5E03\u3092\u5236\u9650\u3055\u308C\u308B\u53EF\u80FD\u6027\u304C\u3042\u308B\u3002" , "lang" : "ja" } ,      { "type" : "literal", "value" : "BBIBP-CorV \u2014 \u043E\u0434\u043D\u0430 \u0438\u0437 \u0434\u0432\u0443\u0445 \u0446\u0435\u043B\u044C\u043D\u043E\u0432\u0438\u0440\u0438\u043E\u043D\u043D\u044B\u0445 \u0438\u043D\u0430\u043A\u0442\u0438\u0432\u0438\u0440\u043E\u0432\u0430\u043D\u043D\u044B\u0445 \u0432\u0430\u043A\u0446\u0438\u043D \u043F\u0440\u043E\u0442\u0438\u0432 COVID-19, \u0440\u0430\u0437\u0440\u0430\u0431\u0430\u0442\u044B\u0432\u0430\u0435\u043C\u044B\u0445 Sinopharm. \u0412\u0430\u043A\u0446\u0438\u043D\u0430 \u0434\u0432\u0443\u0445\u0434\u043E\u0437\u043E\u0432\u0430\u044F, \u0434\u043B\u044F \u0432\u043D\u0443\u0442\u0440\u0438\u043C\u044B\u0448\u0435\u0447\u043D\u044B\u0445 \u0438\u043D\u044A\u0435\u043A\u0446\u0438\u0439 \u0441 \u0438\u043D\u0442\u0435\u0440\u0432\u0430\u043B\u043E\u043C \u043C\u0435\u0436\u0434\u0443 \u0438\u043D\u044A\u0435\u043A\u0446\u0438\u044F\u043C\u0438 3\u20144 \u043D\u0435\u0434\u0435\u043B\u0438. \u0425\u0440\u0430\u043D\u0438\u0442\u0441\u044F \u043F\u0440\u0438 \u0442\u0435\u043C\u043F\u0435\u0440\u0430\u0442\u0443\u0440\u0435 2\u20138 \u00B0C. \u041F\u043E \u0441\u043E\u0441\u0442\u043E\u044F\u043D\u0438\u044E \u043D\u0430 \u0434\u0435\u043A\u0430\u0431\u0440\u044C 2020 \u0433\u043E\u0434\u0430 \u043E\u043D\u0430 \u043F\u0440\u043E\u0445\u043E\u0434\u0438\u043B\u0430 III \u0444\u0430\u0437\u0443 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u0439 \u0432 \u0410\u0440\u0433\u0435\u043D\u0442\u0438\u043D\u0435, \u0411\u0430\u0445\u0440\u0435\u0439\u043D\u0435, \u0415\u0433\u0438\u043F\u0442\u0435, \u041C\u0430\u0440\u043E\u043A\u043A\u043E, \u041F\u0430\u043A\u0438\u0441\u0442\u0430\u043D\u0435, \u041F\u0435\u0440\u0443 \u0438 \u041E\u0431\u044A\u0435\u0434\u0438\u043D\u0451\u043D\u043D\u044B\u0445 \u0410\u0440\u0430\u0431\u0441\u043A\u0438\u0445 \u042D\u043C\u0438\u0440\u0430\u0442\u0430\u0445 (\u041E\u0410\u042D), \u0432 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u0438 \u0443\u0447\u0430\u0441\u0442\u0432\u043E\u0432\u0430\u043B\u043E \u0431\u043E\u043B\u0435\u0435 60 000 \u0447\u0435\u043B\u043E\u0432\u0435\u043A. \u041A \u043D\u043E\u044F\u0431\u0440\u044E 2020 \u0433\u043E\u0434\u0430 \u043F\u043E\u0447\u0442\u0438 \u043C\u0438\u043B\u043B\u0438\u043E\u043D \u0447\u0435\u043B\u043E\u0432\u0435\u043A \u043F\u0440\u043E\u0448\u043B\u0438 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u0446\u0438\u044E \u0432 \u0440\u0430\u043C\u043A\u0430\u0445 \u043A\u0438\u0442\u0430\u0439\u0441\u043A\u043E\u0439 \u043F\u0440\u043E\u0433\u0440\u0430\u043C\u043C\u044B \u044D\u043A\u0441\u0442\u0440\u0435\u043D\u043D\u043E\u0433\u043E \u0438\u0441\u043F\u043E\u043B\u044C\u0437\u043E\u0432\u0430\u043D\u0438\u044F. \u041A \u0434\u0435\u043A\u0430\u0431\u0440\u044E 2020 \u0433\u043E\u0434\u0430 \u043F\u043E\u0447\u0442\u0438 100 000 \u0447\u0435\u043B\u043E\u0432\u0435\u043A \u0432 \u041E\u0410\u042D \u0442\u0430\u043A\u0436\u0435 \u043F\u043E\u043B\u0443\u0447\u0438\u043B\u0438 \u0432\u0430\u043A\u0446\u0438\u043D\u0443 \u0432 \u0440\u0430\u043C\u043A\u0430\u0445 \u0434\u043E\u0431\u0440\u043E\u0432\u043E\u043B\u044C\u043D\u043E\u0439 \u043F\u0440\u043E\u0433\u0440\u0430\u043C\u043C\u044B. 9 \u0434\u0435\u043A\u0430\u0431\u0440\u044F 2020 \u0433\u043E\u0434\u0430 \u041E\u0410\u042D \u043E\u0431\u044A\u044F\u0432\u0438\u043B\u0438 \u043E\u0431 \u043E\u0444\u0438\u0446\u0438\u0430\u043B\u044C\u043D\u043E\u0439 \u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0430\u0446\u0438\u0438 BBICP-CorV \u043F\u043E\u0441\u043B\u0435 \u0442\u043E\u0433\u043E, \u043A\u0430\u043A \u043F\u0440\u043E\u043C\u0435\u0436\u0443\u0442\u043E\u0447\u043D\u044B\u0439 \u0430\u043D\u0430\u043B\u0438\u0437 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u0439 \u0444\u0430\u0437\u044B III \u043F\u043E\u043A\u0430\u0437\u0430\u043B, \u0447\u0442\u043E \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C BBIBP-CorV \u043F\u0440\u043E\u0442\u0438\u0432 \u0438\u043D\u0444\u0435\u043A\u0446\u0438\u0438 COVID-19 \u0441\u043E\u0441\u0442\u0430\u0432\u043B\u044F\u0435\u0442 86%. \u0418 \u0411\u0430\u0445\u0440\u0435\u0439\u043D, \u0438 \u041E\u0410\u042D \u043E\u0434\u043E\u0431\u0440\u0438\u043B\u0438 \u0438\u0441\u043F\u043E\u043B\u044C\u0437\u043E\u0432\u0430\u043D\u0438\u0435 \u0432\u0430\u043A\u0446\u0438\u043D\u044B. \u0412 \u041E\u0410\u042D \u043D\u0435 \u0441\u043E\u043E\u0431\u0449\u0438\u043B\u0438, \u043A\u0430\u043A \u0431\u0443\u0434\u0435\u0442 \u0440\u0430\u0437\u0432\u043E\u0440\u0430\u0447\u0438\u0432\u0430\u0442\u044C\u0441\u044F \u0432\u0430\u043A\u0446\u0438\u043D\u0438\u0440\u043E\u0432\u0430\u043D\u0438\u0435. 12 \u0434\u0435\u043A\u0430\u0431\u0440\u044F 2020 \u0433\u043E\u0434\u0430 \u041F\u0435\u0440\u0443 \u043F\u0440\u0438\u043E\u0441\u0442\u0430\u043D\u043E\u0432\u0438\u043B\u043E \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F \u0432\u0430\u043A\u0446\u0438\u043D\u044B Sinopharm \u0434\u043B\u044F \u0440\u0430\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F \u043F\u043E\u0431\u043E\u0447\u043D\u043E\u0433\u043E \u044D\u0444\u0444\u0435\u043A\u0442\u0430, \u043A\u043E\u0442\u043E\u0440\u044B\u0439 \u0431\u044B\u043B \u043E\u0431\u043D\u0430\u0440\u0443\u0436\u0435\u043D \u0443 \u043E\u0434\u043D\u043E\u0433\u043E \u0438\u0437 \u0434\u043E\u0431\u0440\u043E\u0432\u043E\u043B\u044C\u0446\u0435\u0432, \u0438 \u0432\u043E\u0437\u043E\u0431\u043D\u043E\u0432\u0438\u043B\u043E \u0438\u0445 16 \u0434\u0435\u043A\u0430\u0431\u0440\u044F. 31 \u0434\u0435\u043A\u0430\u0431\u0440\u044F 2020 \u0433\u043E\u0434\u0430 \u041D\u0430\u0446\u0438\u043E\u043D\u0430\u043B\u044C\u043D\u0430\u044F \u043A\u043E\u043C\u0438\u0441\u0441\u0438\u044F \u0437\u0434\u0440\u0430\u0432\u043E\u043E\u0445\u0440\u0430\u043D\u0435\u043D\u0438\u044F \u041A\u0438\u0442\u0430\u0439\u0441\u043A\u043E\u0439 \u041D\u0430\u0440\u043E\u0434\u043D\u043E\u0439 \u0420\u0435\u0441\u043F\u0443\u0431\u043B\u0438\u043A\u0438 \u043E\u0434\u043E\u0431\u0440\u0438\u043B\u0430 \u0432\u0430\u043A\u0446\u0438\u043D\u0443 BBIBP-CorV \u0434\u043B\u044F \u0448\u0438\u0440\u043E\u043A\u043E\u0433\u043E \u0438\u0441\u043F\u043E\u043B\u044C\u0437\u043E\u0432\u0430\u043D\u0438\u044F \u043A\u0430\u043A \u043F\u0435\u0440\u0432\u0443\u044E \u0432\u0430\u043A\u0446\u0438\u043D\u0443 \u043E\u0442 \u043A\u043E\u0440\u043E\u043D\u0430\u0432\u0438\u0440\u0443\u0441\u0430 \u0441\u043E\u0431\u0441\u0442\u0432\u0435\u043D\u043D\u043E\u0433\u043E \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0441\u0442\u0432\u0430. \u041E\u0434\u043E\u0431\u0440\u0435\u043D\u0438\u0435 \u0431\u044B\u043B\u043E \u043F\u043E\u043B\u0443\u0447\u0435\u043D\u043E \u043D\u0430 \u0441\u043B\u0435\u0434\u0443\u044E\u0449\u0438\u0439 \u0434\u0435\u043D\u044C \u043F\u043E\u0441\u043B\u0435 \u0442\u043E\u0433\u043E, \u043A\u0430\u043A \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0438\u0442\u0435\u043B\u044C, Sinopharm, \u0437\u0430\u044F\u0432\u0438\u043B, \u0447\u0442\u043E \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C \u0432\u0430\u043A\u0446\u0438\u043D\u044B \u0441\u043E\u0441\u0442\u0430\u0432\u043B\u044F\u0435\u0442 79,34 % \u043F\u043E \u0440\u0435\u0437\u0443\u043B\u044C\u0442\u0430\u0442\u0430\u043C \u043F\u0440\u043E\u043C\u0435\u0436\u0443\u0442\u043E\u0447\u043D\u043E\u0433\u043E \u0430\u043D\u0430\u043B\u0438\u0437\u0430 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0438\u0441\u043F\u044B\u0442\u0430\u043D\u0438\u0439 \u0444\u0430\u0437\u044B III. BBIBP-CorV \u0438\u0441\u043F\u043E\u043B\u044C\u0437\u0443\u0435\u0442 \u0430\u043D\u0430\u043B\u043E\u0433\u0438\u0447\u043D\u0443\u044E, \u0431\u043E\u043B\u0435\u0435 \u0442\u0440\u0430\u0434\u0438\u0446\u0438\u043E\u043D\u043D\u0443\u044E \u0442\u0435\u0445\u043D\u043E\u043B\u043E\u0433\u0438\u044E, \u0447\u0442\u043E \u0438 \u0432 CoronaVac, BBV152, \u041A\u043E\u0432\u0438\u0412\u0430\u043A \u0438 \u0434\u0440\u0443\u0433\u0438\u0445 \u0438\u043D\u0430\u043A\u0442\u0438\u0432\u0438\u0440\u043E\u0432\u0430\u043D\u043D\u044B\u0445 \u0446\u0435\u043B\u044C\u043D\u043E\u0432\u0438\u0440\u0443\u0441\u043D\u044B\u0445 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u0445 \u043F\u0440\u043E\u0442\u0438\u0432 COVID-19, \u043F\u0440\u043E\u0445\u043E\u0434\u044F\u0449\u0438\u0445 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F III \u0444\u0430\u0437\u044B. \u0422\u0430\u043A\u0430\u044F \u0442\u0435\u0445\u043D\u043E\u043B\u043E\u0433\u0438\u044F \u0443\u0441\u043F\u0435\u0448\u043D\u043E \u043F\u0440\u0438\u043C\u0435\u043D\u044F\u0435\u0442\u0441\u044F \u0432\u043E \u043C\u043D\u043E\u0433\u0438\u0445 \u0445\u043E\u0440\u043E\u0448\u043E \u0438\u0437\u0432\u0435\u0441\u0442\u043D\u044B\u0445 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u0445, \u0442\u0430\u043A\u0438\u0445 \u043A\u0430\u043A \u0432\u0430\u043A\u0446\u0438\u043D\u0430 \u043F\u0440\u043E\u0442\u0438\u0432 \u0431\u0435\u0448\u0435\u043D\u0441\u0442\u0432\u0430. \u041C\u0438\u043D\u0438\u0441\u0442\u0435\u0440\u0441\u0442\u0432\u043E \u0437\u0434\u0440\u0430\u0432\u043E\u043E\u0445\u0440\u0430\u043D\u0435\u043D\u0438\u044F \u0410\u0440\u0433\u0435\u043D\u0442\u0438\u043D\u044B \u0441\u043E\u043E\u0431\u0449\u0438\u043B\u043E 1 \u0438\u044E\u043B\u044F 2021, \u0447\u0442\u043E, \u043F\u043E \u043F\u0440\u0435\u0434\u0432\u0430\u0440\u0438\u0442\u0435\u043B\u044C\u043D\u044B\u043C \u0440\u0435\u0437\u0443\u043B\u044C\u0442\u0430\u0442\u0430\u043C \u043D\u0430 \u0432\u044B\u0431\u043E\u0440\u043A\u0435 \u0438\u0437 471 682 \u0430\u0440\u0433\u0435\u043D\u0442\u0438\u043D\u0446\u0435\u0432 \u0432\u043E\u0437\u0440\u0430\u0441\u0442\u043E\u043C \u0441\u0442\u0430\u0440\u0448\u0435 60 \u043B\u0435\u0442 \u0432 \u0444\u0435\u0432\u0440\u0430\u043B\u0435-\u0438\u044E\u043D\u0435 2021, \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C \u043F\u0440\u043E\u0442\u0438\u0432 \u0441\u043C\u0435\u0440\u0442\u0438 \u043E\u0442 COVID-19 \u0441\u043E\u0441\u0442\u0430\u0432\u043B\u044F\u0435\u0442 61,6% \u0434\u043B\u044F \u043F\u0435\u0440\u0432\u043E\u0439 \u0434\u043E\u0437\u044B \u0432\u0430\u043A\u0446\u0438\u043D\u044B BBIBP-CorV \u043E\u0442 Sinopharm \u0438 84,0% \u0434\u043B\u044F \u043F\u043E\u043B\u043D\u043E\u0433\u043E \u0434\u0432\u0443\u0445\u0434\u043E\u0437\u043E\u0432\u043E\u0433\u043E \u043A\u0443\u0440\u0441\u0430 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u0446\u0438\u0438 (\u0434\u043B\u044F \u0441\u0440\u0430\u0432\u043D\u0435\u043D\u0438\u044F, \u0432 \u0442\u0435\u0445 \u0436\u0435 \u0443\u0441\u043B\u043E\u0432\u0438\u044F\u0445 \u0432\u0430\u043A\u0446\u0438\u043D\u0430 AstraZeneca \u043F\u043E\u043A\u0430\u0437\u0430\u043B\u0430 \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C 79,5% \u0438 88,8%, \u0432\u0430\u043A\u0446\u0438\u043D\u0430 \u00AB\u0421\u043F\u0443\u0442\u043D\u0438\u043A V\u00BB \u2014 74,9 % \u0438 93,3%)." , "lang" : "ru" } ,      { "type" : "literal", "value" : "La BBIBP-CorV \u00E9s una de les dues vacunes contra la COVID-19 de virus inactivats que desenvolupa Sinopharm. A desembre de 2020, es troba en proves de fase III a Argentina, Bahrain, Egipte, Marroc, Pakistan, Per\u00FA i els Emirats \u00C0rabs Units (EAU) amb m\u00E9s de 60.000 participants. Al novembre, a gaireb\u00E9 un mili\u00F3 de persones se'ls havia administrat la vacuna mitjan\u00E7ant el programa d'\u00FAs d'emerg\u00E8ncia de la Xina. Al desembre, gaireb\u00E9 100.000 persones als Emirats \u00C0rabs Units tamb\u00E9 havien rebut la vacuna. El 9 de desembre, els Emirats \u00C0rabs Units van anunciar el registre oficial de BBICP-CorV despr\u00E9s que una an\u00E0lisi provisional dels assaigs de fase III va demostrar que BBIBP-CorV tenia una efic\u00E0cia del 86% contra la infecci\u00F3 per COVID-19. Tant Bahrain com els Emirats \u00C0rabs Units van aprovar la vacuna per al seu \u00FAs. El 12 de desembre, Per\u00FA va suspendre els assaigs per a la vacuna de Sinopharm per investigar un esdeveniment advers que va oc\u00F3rrer amb un dels voluntaris abans de reprendre els assaigs el 16 de desembre. BBIBP-CorV utilitza una tecnologia similar a CoronaVac o BBV152, i a altres vacunes contra virus inactivats per al COVID-19 que es desenvolupen en assajos de fase III." , "lang" : "ca" } ] ,    "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Variants_of_SARS-CoV-2" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mongolia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Montenegro" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Maldives" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/UAE" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Inactivated_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/MRNA" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Cayetano_Heredia_University" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Georgia_(country)" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Angola" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Armenia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Serbia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Belarus" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/List_of_COVID-19_vaccine_authorizations" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Severe_acute_respiratory_syndrome_coronavirus_2" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Venezuela" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Intramuscular_injection" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/GAVI" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Antibody" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Vientiane" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Papua_New_Guinea" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/SARS-CoV-2_Delta_variant" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Peru" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Equatorial_Guinea" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mauritania" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Argentina" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Solomon_Islands" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Rodrigo_Duterte" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Seychelles" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Immunologic_adjuvant" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mozambique" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Clinical_trials" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Viktor_Orb\u00E1n" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Aluminium_hydroxide" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Namibia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/T_cell" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Inactivated_vaccines" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Products_introduced_in_2020" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sierra_Leone" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Cameroon" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Somalia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Bangladesh" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Ethiopia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sputnik_V_COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Brunei" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Hungary" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Singapore" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Symptoms_of_COVID-19" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/World_Health_Organization" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Kenya" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Bahrain" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Cambodia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Dominican_Republic" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Severity_of_illness" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Senegal" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/COVAX" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/State_of_Palestine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Indonesia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Republic_of_the_Congo" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Asymptomatic_carrier" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Covaxin" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/CoronaVac" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sudan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/United_Arab_Emirates" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Lebanon" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Pakistan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Macau" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mexico" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Vietnam" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Jordan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Iraq" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Philippines" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Vero_cell" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Barbados" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Egypt" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Casablanca" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/ZF2001" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sri_Lanka" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Kyrgyzstan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Gabon" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/China" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Morocco" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Libya" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Algeria" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/North_Macedonia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Covishield" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Phases_of_clinical_research" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Trinidad_and_Tobago" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/SARS-CoV-2_Lambda_variant" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/University_of_Karachi" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Kazakhstan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/European_Medicines_Agency" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Zimbabwe" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/COVID-19" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Abdel_Fattah_el-Sisi" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Beta-propiolactone" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/File:BBIBP-CorV_Vaccination_Certificate.jpg" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Category:Chinese_COVID-19_vaccines" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Pre-print" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mart\u00EDn_Vizcarra" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/National_Medical_Products_Administration" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Oxford\u2013AstraZeneca_COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Guyana" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Polio_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Thailand" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Rabat" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Moderna_COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/SARS-CoV-2_Gamma_variant" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mia_Mottley" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/SARS-CoV-2_Alpha_variant" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/JAMA" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/SARS-CoV-2_Beta_variant" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Turkmenistan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Pfizer\u2013BioNTech_COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Syria" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Booster_dose" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_WIBP_COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Inpatient_care" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Afghanistan" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Nepal" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Iran" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Deltoid_muscle" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Laos" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Ministry_of_Health_(Argentina)" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Memory_B_cell" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Confidence_interval" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Seroconversion" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Developing_world" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/The_New_York_Times" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Bosnia_and_Herzegovina" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Emergency_use_authorization" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Bolivia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Abu_Dhabi" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Dominica" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Mauritius" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Moldova" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Niger" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Zambia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/ULT_freezer" } ] ,    "http://dbpedia.org/property/wikiPageUsesTemplate" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Cite_news" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Scholia" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Infobox_drug" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Vaccines" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:COVID-19_pandemic" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:COVID-19_pandemic_sidebar" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:!" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Authority_control" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Short_description" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Main" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Use_dmy_dates" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:N/a" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Shade" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Pp-semi-indef" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Other_uses" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Reflist" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Estimate" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Efn-ua" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Notelist-ua" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:Portal_bar" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Template:See_also" } ] ,    "http://dbpedia.org/ontology/thumbnail" : [ { "type" : "uri", "value" : "http://commons.wikimedia.org/wiki/Special:FilePath/Sinopharm_BBIBP-CorV_COVID-19_vaccine_vial_from_Nikli,_Bangladesh.jpg?width=300" } ] ,    "http://dbpedia.org/ontology/wikiPageRevisionID" : [ { "type" : "literal", "value" : 1119662075 , "datatype" : "http://www.w3.org/2001/XMLSchema#integer" } ] ,    "http://dbpedia.org/ontology/wikiPageExternalLink" : [ { "type" : "uri", "value" : "https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html" } ] ,    "http://dbpedia.org/ontology/wikiPageLength" : [ { "type" : "literal", "value" : "90715" , "datatype" : "http://www.w3.org/2001/XMLSchema#nonNegativeInteger" } ] ,    "http://dbpedia.org/ontology/wikiPageID" : [ { "type" : "literal", "value" : 66089296 , "datatype" : "http://www.w3.org/2001/XMLSchema#integer" } ] ,    "http://dbpedia.org/property/caption" : [ { "type" : "literal", "value" : "A vial of the BBIBP-CorV COVID-19 vaccine" , "lang" : "en" } ] ,    "http://www.w3.org/2002/07/owl#sameAs" : [ { "type" : "uri", "value" : "http://it.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://th.dbpedia.org/resource/\u0E27\u0E31\u0E04\u0E0B\u0E35\u0E19\u0E42\u0E04\u0E27\u0E34\u0E14-19_BBIBP-CorV_\u0E02\u0E2D\u0E07\u0E0B\u0E34\u0E42\u0E19\u0E1F\u0E32\u0E23\u0E4C\u0E21" } ,      { "type" : "uri", "value" : "http://ru.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://ko.dbpedia.org/resource/\uC2DC\uB178\uD31C_BBIBP-CorV_\uCF54\uB85C\uB09819_\uBC31\uC2E0" } ,      { "type" : "uri", "value" : "http://es.dbpedia.org/resource/Vacuna_de_Sinopharm_contra_la_COVID-19" } ,      { "type" : "uri", "value" : "http://de.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://zh.dbpedia.org/resource/\u773E\u611B\u53EF\u7DAD2019\u51A0\u72C0\u75C5\u6BD2\u75C5\u75AB\u82D7" } ,      { "type" : "uri", "value" : "http://no.dbpedia.org/resource/Sinopharms_COVID-19-vaksine_(BBIBP-CorV)" } ,      { "type" : "uri", "value" : "http://hu.dbpedia.org/resource/Sinopharm-Covid19-vakcina" } ,      { "type" : "uri", "value" : "http://uk.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://id.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://fr.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://cs.dbpedia.org/resource/Vakc\u00EDna_Sinopharm_BIBP_proti_covidu-19" } ,      { "type" : "uri", "value" : "http://tl.dbpedia.org/resource/Sinopharm_BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://sv.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://vi.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://ca.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://eo.dbpedia.org/resource/Vakcino_de_la_kronvirusa_malsano_de_2019_de_Sinopharm_BIBP" } ,      { "type" : "uri", "value" : "http://mk.dbpedia.org/resource/\u0411\u0411\u0418\u0411\u041F-\u041A\u043E\u0440\u0412" } ,      { "type" : "uri", "value" : "http://ms.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://pt.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ,      { "type" : "uri", "value" : "http://uz.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://nl.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://www.wikidata.org/entity/Q97154230" } ,      { "type" : "uri", "value" : "http://bn.dbpedia.org/resource/\u09B8\u09BF\u09A8\u09CB\u09AB\u09BE\u09B0\u09CD\u09AE_\u09AC\u09BF\u09AC\u09BF\u0986\u0987\u09AC\u09BF\u09AA\u09BF-\u0995\u09B0\u09CD\u09AD\u09BF_\u0995\u09CB\u09AD\u09BF\u09A1-\u09E7\u09EF_\u099F\u09BF\u0995\u09BE" } ,      { "type" : "uri", "value" : "https://global.dbpedia.org/id/FT7cv" } ,      { "type" : "uri", "value" : "http://ar.dbpedia.org/resource/BBIBP-CorV" } ,      { "type" : "uri", "value" : "http://fa.dbpedia.org/resource/\u0648\u0627\u06A9\u0633\u0646_\u06A9\u0648\u0648\u06CC\u062F-\u06F1\u06F9_\u0633\u06CC\u0646\u0648\u0641\u0627\u0631\u0645" } ,      { "type" : "uri", "value" : "http://ja.dbpedia.org/resource/\u30B7\u30CE\u30D5\u30A1\u30FC\u30E0COVID-19\u30EF\u30AF\u30C1\u30F3" } ] ,    "http://www.w3.org/ns/prov#wasDerivedFrom" : [ { "type" : "uri", "value" : "http://en.wikipedia.org/wiki/Sinopharm_BIBP_COVID-19_vaccine?oldid=1119662075&ns=0" } ] ,    "http://dbpedia.org/property/type" : [ { "type" : "literal", "value" : "vaccine" , "lang" : "en" } ] ,    "http://xmlns.com/foaf/0.1/isPrimaryTopicOf" : [ { "type" : "uri", "value" : "http://en.wikipedia.org/wiki/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/property/atcSuffix" : [ { "type" : "literal", "value" : "BX03" , "lang" : "en" } ] ,    "http://dbpedia.org/property/target" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Severe_acute_respiratory_syndrome_coronavirus_2" } ] ,    "http://dbpedia.org/property/routesOfAdministration" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Intramuscular_injection" } ] ,    "http://dbpedia.org/property/casNumber" : [ { "type" : "literal", "value" : 2503126 , "datatype" : "http://www.w3.org/2001/XMLSchema#integer" } ] ,    "http://dbpedia.org/property/atcPrefix" : [ { "type" : "literal", "value" : "J07" , "lang" : "en" } ] ,    "http://dbpedia.org/ontology/casNumber" : [ { "type" : "literal", "value" : "2503126-65-4" } ] ,    "http://dbpedia.org/property/vaccineType" : [ { "type" : "literal", "value" : "inactivated" , "lang" : "en" } ] ,    "http://dbpedia.org/property/drugName" : [ { "type" : "literal", "value" : "BBIBP-CorV" , "lang" : "en" } ] ,    "http://dbpedia.org/property/legalStatus" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/List_of_COVID-19_vaccine_authorizations" } ] ,    "http://dbpedia.org/property/synonyms" : [ { "type" : "literal", "value" : "Zhong'aikewei , Hayat-Vax" , "lang" : "en" } ] ,    "http://dbpedia.org/ontology/drugbank" : [ { "type" : "literal", "value" : "DB15807" } ] ,    "http://dbpedia.org/property/drugbank" : [ { "type" : "literal", "value" : "DB15807" , "lang" : "en" } ] ,    "http://dbpedia.org/property/legalBr" : [ { "type" : "literal", "value" : "Emergency use" , "lang" : "en" } ] } ,  "http://dbpedia.org/resource/Timeline_of_the_COVID-19_pandemic_in_the_Philippines_(2020)" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2021_in_Indonesia" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Iraq" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinopharm_WIBP_COVID-19_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2020_Summer_Olympics" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Deployment_of_COVID-19_vaccines" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/International_inequality" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Cambodia" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2021_in_China" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2021_in_Sri_Lanka" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/CoronaVac" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/SARS-CoV-2_Beta_variant" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Timeline_of_the_COVID-19_pandemic_in_the_Philippines_(2021)" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinovac_Biotech" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Fawziya_Abikar_Nur" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Bahrain" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Bangladesh" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Belarus" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Belize" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Burundi" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Cameroon" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Chad" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Cuba" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Egypt" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Equatorial_Guinea" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Gabon" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Maldives" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Mauritania" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Moldova" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Morocco" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Papua_New_Guinea" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Peru" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Senegal" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_South_Asia" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Sri_Lanka" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Vanuatu" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Vietnam" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Zimbabwe" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_the_Republic_of_the_Congo" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_the_United_Arab_Emirates" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Brazil" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Kazakhstan" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Singapore" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_the_Philippines" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVIran_Barekat" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Turkmenistan" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Responses_to_the_COVID-19_pandemic_in_May_2021" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Egypt" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Angola" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Hungary" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Vaccine_diplomacy" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Timeline_of_the_COVID-19_pandemic_in_Pakistan" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Pakistan" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Venezuela" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_the_State_of_Palestine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Social_impact_of_the_COVID-19_pandemic_in_Malaysia" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sputnik_V_COVID-19_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Human_rights_issues_related_to_the_COVID-19_pandemic" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Nigeria" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2021_in_Gabon" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Vietnam" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Argentina" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Thailand" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Imran_Khan" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Luis_Arce" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Moldova" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Australia" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Burundi" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccine_clinical_research" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/List_of_vaccine_topics" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/List_of_COVID-19_vaccine_authorizations" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Rodrigo_Duterte" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/SARS-CoV-2_Delta_variant" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Argentina" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Indonesia" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Sri_Lanka" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Hungary" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Bulgaria" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Responses_to_the_COVID-19_pandemic_in_November_2021" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/FAKHRAVAC" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/My_Vaccine_Pass" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Peru" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2021_in_Peru" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Mauro_Viale" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/China\u2013Equatorial_Guinea_relations" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/China\u2013Moldova_relations" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/China\u2013Morocco_relations" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_pandemic_in_Seychelles" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Bangladesh" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Bhutan" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Cameroon" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Chad" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Equatorial_Guinea" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Nepal" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_the_Comoros" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Mexico" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/\u0160efik_D\u017Eaferovi\u0107" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/2021_in_Venezuela" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/International_aid_related_to_the_COVID-19_pandemic" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVAX" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Africa" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_South_Africa" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/World_Health_Organization's_response_to_the_COVID-19_pandemic" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/History_of_COVID-19_vaccine_development" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Fadil_Novali\u0107" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Zimbabwe" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Senegal" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sputnik_Light" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Razi_Cov_Pars" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/\u00C9variste_Ndayishimiye" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_Bosnia_and_Herzegovina" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/BBIBP-CorV" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageRedirects" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinopharm_BBIBP-CorV_COVID-19_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageRedirects" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinopharm_(disambiguation)" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageDisambiguates" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinopharm_COVID-19_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/BBIBP" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageRedirects" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Hayat-Vax" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageRedirects" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Sinopharm_BIBP_COVID\u201119_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageRedirects" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Vero_Cell_COVID-19_vaccine" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] ,    "http://dbpedia.org/ontology/wikiPageRedirects" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/Timeline_of_the_COVID-19_pandemic_in_Singapore_(2021)" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] } ,  "http://dbpedia.org/resource/COVID-19_vaccination_in_mainland_China" : { "http://dbpedia.org/ontology/wikiPageWikiLink" : [ { "type" : "uri", "value" : "http://dbpedia.org/resource/Sinopharm_BIBP_COVID-19_vaccine" } ] }}